

# Brennan Spiegel, MD, MSHS, FACG – *Curriculum Vitae*

---

## PERSONAL HISTORY

**Business Address:** West Los Angeles VA Medical Center  
 David Geffen School of Medicine at UCLA  
 UCLA/VA Center for Outcomes Research and Education (CORE)  
 CURE Digestive Diseases Research Center  
 11301 Wilshire Blvd  
 Bldg 115 Room 215E  
 Los Angeles, California 90073  
 Phone: (310) 268-3256  
 Fax: (310) 268-4510  
 Personal Email: [bspiegel@mednet.ucla.edu](mailto:bspiegel@mednet.ucla.edu)  
 UCLA/VA CORE Website: [www.ResearchCORE.org](http://www.ResearchCORE.org)

## Personal Data / Staff Contact Information:

**Date of Birth:** 8/28/72  
**Place of Birth:** Los Angeles, California  
**Citizenship:** United States  
**Administrative Assistants:** Jesse Delgado ([jdeldgado@mednet.ucla.edu](mailto:jdeldgado@mednet.ucla.edu))  
 Bradley Snyder ([brsnnyder@mednet.ucla.edu](mailto:brsnnyder@mednet.ucla.edu))  
**UCLA Fellowship Coordinator:** Kathy Oka ([koka@mednet.ucla.edu](mailto:koka@mednet.ucla.edu))  
**Research Assistants** Jennifer Talley ([jtalley@mednet.ucla.edu](mailto:jtalley@mednet.ucla.edu))  
 Radha Bathala ([radha.bathala@gmail.com](mailto:radha.bathala@gmail.com))

## EDUCATION

1990 - 1994 **Tufts University**, Medford, Massachusetts  

- BA in **Philosophy**, *cum laude*, May 1994
- Certificate in **Community Health**, May 1994

1994 - 1998 **New York Medical College**, Valhalla, New York  

- MD Degree, *Alpha Omega Alpha*, May 1998

1998 - 2001 Resident, Department of Internal Medicine, **Cedars-Sinai Medical Center**, Los Angeles, California  

2001 – 2004 Fellow, **UCLA Training Program in Digestive Diseases**  

2002 – 2004 **University of California Los Angeles School of Public Health**  

- Master's Degree in Health Services - **MSHS**

## LICENSURE / BOARD CERTIFICATION

National Board of Medical Examiners I, II, III	1996, 1997, 2000
Medical Board of California	License #A70587
American Board of Internal Medicine	September 2001 (valid through 9/2011)
ABIM Gastroenterology Certification	October 2004 (valid through 10/2014)

## POSITIONS AND PROFESSIONAL EXPERIENCE

- 1998 - 2000 *Research Associate, Cedars-Sinai Medical Center, Departments of Gastroenterology and Health Services Research*, Los Angeles, California. Emphasis on evidence-based outcomes research. Research included a systematic review of the effectiveness of early endoscopy for acute non-variceal upper gastrointestinal tract hemorrhage, a cost-effectiveness analysis of competing management strategies for uninvestigated dyspepsia, and an economic model of strategies for the post-hemostasis management of peptic ulcer hemorrhage.
- 1999 - 2004 *Research Consultant, Zynx Health Incorporated*, Beverly Hills, California. Research included a cost-effectiveness analysis of competing proton pump inhibitors in erosive esophagitis, a systematic review of biological agents in rheumatoid arthritis, and a pharmacoeconomic analysis of adjuvant darbepoetin therapy in hepatitis C. Related skills include systematic review, study quality evaluation, meta-analysis, survey design and administration, computerized decision analysis (proficient in TreeAge DATA Software), Markov modeling, probabilistic (Monte Carlo) simulation modeling, budget impact modeling, and multivariable regression analysis (proficient in STATA).
- 2001 - 2004 *Research Fellow, Center for the Study of Digestive Healthcare Quality and Outcomes*, Los Angeles, California. Research emphasis on economics of clinical practice in gastroenterology. Projects included cost-effectiveness analyses of management strategies for primary and secondary prophylaxis of variceal hemorrhage and an economic evaluation of COX-2 selective inhibitors in chronic arthritis.
- 2002 - 2004 *Research Fellow, Center for Neurovisceral Sciences and Women's Health*, Los Angeles, California. Research emphasis on economics and health-related quality of life in irritable bowel syndrome (IBS). Projects included an analysis evaluating the association between a negative colonoscopy and reassurance in IBS, an analysis evaluating clinical determinants of quality of life in IBS, a randomized trial comparing a "model physician patient relationship" versus usual care in IBS, a cost-effectiveness analysis evaluating screening for celiac sprue in IBS, and a database analysis measuring the relationship between somatization and resource utilization in IBS. .
- 2004 - 2009 *Assistant Professor In-Residence, David Geffen School of Medicine at UCLA*, Department of Medicine, Division of Digestive Diseases.
- 2004 – 2005 *Co-Director, Center for the Study of Digestive Healthcare Quality and Outcomes*, Los Angeles, California.
- 2005 – Present *Director, UCLA/VA Center for Outcomes Research and Education (CORE)*, Los Angeles, California. ([www.ResearchCORE.org](http://www.ResearchCORE.org))
- 2005 – 2009 *Co-Director, Health Outcomes Core, Center for Neurovisceral Sciences and Women's Health*, Los Angeles, California.
- 2005 – Present *Section Chief, Outcomes Research, UCLA Division of Digestive Diseases*
- 2007 – Present *Adjunct Faculty, UCLA School of Public Health*, Department of Health Services Research
- 2008 – Present *Section Chief, Education and Training, UCLA Division of Digestive Diseases*
- 2008 - Present *Program Director, UCLA Fellowship Program in Gastroenterology.*
- July 2010 *Associate Professor In-Residence, Step II, David Geffen School of Medicine at UCLA*, Department of Medicine, Division of Digestive Diseases

## PROFESSIONAL ACTIVITIES

### PROFESSIONAL ASSOCIATIONS / SCHOLARY SOCIETIES / MEMBERSHIPS

2008 - Present	Fellow, American College of Gastroenterology (FACG)
2006 - 2008	Member, American College of Gastroenterology (ACG)
2010- Present	American Neurogastroenterology and Motility Society (ANMS)
2006 - Present	Rome Committee on Functional Gastrointestinal Disorders
2005 - Present	American Society for Gastrointestinal Endoscopy (ASGE)
2004 - Present	CURE Digestive Diseases Research Center
2003 - Present	Center for Neurobiology of Stress
2003 - Present	Functional Brain-Gut Research Group
2002 – 2004	Society for Medical Decision Making
2002 - Present	Gastroenterology Research Group (GRG)
2001 - Present	American Gastroenterological Association (AGA)
1999 - Present	California Medical Board
1999 - Present	American College of Physicians
1998 - Present	Alpha Omega Alpha National Medical Honors Society
1994 - Present	American Medical Association
1994 - Present	Golden Key National Honors Society

### EDITORIAL POSITIONS

2009 – Present	<b>American Journal of Gastroenterology</b> , Associate Editor (Outcomes research, Functional GI)
2009 – Present	<b>Alimentary Pharmacology &amp; Therapeutics (APT)</b> , Member, International Editorial Board
2008 – Present	<b>Clinical Gastroenterology and Hepatology</b> , Member, Advisory Board of Editors

### AD HOC REVIEWER

<b>Alimentary Pharmacology and Therapeutics</b> , External Peer Reviewer (2003 – Present)
<b>Annals of Internal Medicine</b> , External Peer Reviewer (2006 – Present)
<b>American Journal of Gastroenterology</b> , External Peer Reviewer (2003 – Present)
<b>Clinical Gastroenterology and Hepatology</b> , External Peer Reviewer (2005 – Present)
<b>Digestive Diseases and Sciences</b> , External Peer Reviewer (2009 – Present)
<b>Evidence-Based Gastroenterology</b> , Editorial Contributor (2002 – 2008)
<b>Gastroenterology</b> , External Peer Reviewer (2002 – Present)
<b>Gastrointestinal Endoscopy</b> , External Peer Reviewer (2006 – Present)
<b>Gut</b> , External Peer Reviewer (2004 - Present)
<b>Hemodialysis International</b> , External Peer Reviewer (2006 – Present)
<b>Hepatology</b> , External Peer Reviewer (2005 – Present)
<b>International Journal for Quality in Health Care</b> , External Peer Reviewer (2004 – Present)
<b>Journal of Clinical Gastroenterology</b> , External Peer Reviewer (2003 – Present)
<b>Journal of the American Society of Nephrology (JASN)</b> , External Peer Reviewer (2008)
<b>Medical Decision Making</b> , External Peer Reviewer (2004 - Present)
<b>Pharmacoepidemiology</b> , External Peer Reviewer (2005 – Present)
<b>Scandinavian Journal of Rheumatology</b> , External Peer Reviewer (2005 – Present)
<b>Value in Health</b> , External Peer Reviewer (2006)

**GRANT REVIEW COMMITTEES**

VA Rehabilitation R&D Merit Review Committee – February, 2005

American College of Gastroenterology Research Grant Committee – 2009 to Present

**ABSTRACT REVIEW COMMITTEES**

2005 VA HSR&D Meeting – Abstract Review Committee

2006 Digestive Disease Week – Abstract Review Committee (epidemiology section)

2007 Digestive Disease Week – Abstract Review Committee (cost-effectiveness analysis section)

2008 Digestive Disease Week – Abstract Review Committee (cost-effectiveness analysis section)

2009 Digestive Disease Week – Abstract Review Committee (Functional GI Epidemiology & Symptoms)

2009 Digestive Disease Week – Abstract Review Committee (Cost-Effectiveness and Quality of Care)

2009 Digestive Disease Week – Co-Chair, Clinical Practice Program Planning Committee

2010 Digestive Disease Week – Co-Chair, Clinical Practice Program Planning Committee

**EDUCATIONAL / ACADEMIC COMMITTEES**

UCLA Training Program in Gastroenterology – Clinical Track Curriculum Action Committee

UCLA Training Program in Gastroenterology – Fellowship Admissions Committee

UCLA Department of Medicine Morbidity and Mortality Committee (2006-Present)

AGA Clinical Practice Section Program Planning Sub-Committee for Digestive Disease Week 2006 - 2010

Council Member, Southern California Society of Gastroenterology (2005-2010)

Member, CURE Digestive Diseases Research Center annual meeting planning committee (2008, 2009)

Member, CURE Digestive Disease Research Center Board of Directors (2008-Present)

Member, Rome Committee for Severity Measurement in Functional GI Disorders (2008-Present)

Member, Rome Committee for Outcome Assessment in Functional GI Disorders (2008-Present)

**MEDICAL SCHOOL CLASSES & LECTURE SERIES TAUGHT**

Second Year Problem Based Learning (PBL) Block 7 – PBL Group Leader (Fall-Winter 2005-2006)

Second Year Lecture Block 7 – Invited Lecturer (Winter 2006)

Second Year Lecture Block 7 – Invited Lecturer (Winter 2007)

Cedars-Sinai / VA Medicine Program – Core Lecture Series in GI (12 part series, 2006-2007; 2007-2008)

UCLA Affiliated Program in Gastroenterology – Health Services Core Lecture Series (2005-Present)

Health Services 249G (Decision Analysis and Cost-Effectiveness Analysis) – School of Public Health Co-Instructor (2007-Present)

Health Services 249T (Advanced Topics in Decision Analysis and Cost-Effectiveness Analysis) – School of Public Health Co-Instructor (2008-Present)

Course Co-Director, Gastroenterology Research Group (GRG) Annual Conference in Methodologies in Outcomes Research (2007-2009)

## VISITING PROFESSORSHIPS

University of Manitoba Department of Gastroenterology, Winnipeg, Canada – October 2005  
 Case Western Reserve University Department of Gastroenterology, Cleveland, OH – October 2006  
 Northwestern University Department of Gastroenterology, Chicago, IL – October 2006  
 University of Illinois Chicago Department of Gastroenterology, Chicago IL – October 2006  
 University of Miami Department of Gastroenterology, Miami, FL – April 2009  
 University of North Carolina Department of Gastroenterology, Chapel Hill, NC – July 2009  
 Radboud University Nijmegen Medical Center, The Netherlands – October 2010  
 Baylor University, Houston, TX – March 2010  
 Vanderbilt University, Nashville, TN – December 2010

## HOSPITAL STAFF APPOINTMENTS

2004 – Present	West Los Angeles VA Medical Center
2004 – Present	UCLA Ronald Reagan Medical Center
2004 – Present	Santa-Monica / UCLA Hospital

## CONSULTING ACTIVITIES

2008	Appointed to the United States <b>Food and Drug Administration</b> (FDA) Gastroenterology Field Advisory Board
2008	Participant of <b>Rome Foundation</b> Food and Drug Administration liaison group
2008, 2010	Participated in <b>International Foundation for Functional Gastrointestinal Disorder</b> (IFFGD) Congressional Hill Day – interfaced with Senatorial and Congressional staffers to raise awareness about unmet needs in NIH and VA funding for digestive diseases
2008	Member, Vienna International Consensus Committee for Nonvariceal Upper Gastrointestinal Tract Hemorrhage
2008	Member, American College of Gastroenterology Working Group in Irritable Bowel Syndrome (IBS Guideline writing committee for ACG)
Ongoing:	Have served on advisory boards for various pharmaceutical companies, including AstraZeneca, Procter & Gamble, Ironwood, Movetis, Prometheus, Novartis, Rose Pharma A/G, Salix, and Takeda Pharmaceuticals.

**SELECTED MENTEES**

- 2003-2006 **Eric Esrailian, MD, MPH:** Mentor for MPH program and MPH thesis. Dr. Esrailian is now Vice-Chair of the UCLA Division of Digestive Diseases.
- 2004-2007 **Martijn vanOijen, MD, PhD:** PhD thesis mentor through University of Nijmegen, The Netherlands. Dr. vanOijen is now on faculty at the University of Utrecht, The Netherlands.
- 2005-2006 **Gil Melmed, MD:** Fellowship research mentor. Currently adjunct GI faculty at Cedars-Sinai Medical Center.
- 2003-2004 **Vincent DeRosa, MD:** Residency research mentor. Currently GI in private practice in Santa Barbara, California.
- 2004-2005 **Gary Chen, MD:** Residency research mentor. Currently GI in private practice in Las Vegas, Nevada.
- 2004-2005 **Neel Mann, DO:** Residency research mentor. Currently GI faculty at Cedars-Sinai Medical Center.
- 2004-2005 **Jennifer Tan, MD:** Residency research mentor. Currently in GI practice in Kaiser Southern California system.
- 2003-2007 **Mary Farid, DO:** Residency and Fellowship research mentor. Currently on adjunct GI faculty at Olive-View UCLA Medical Center.
- 2004-2008 **Inder Singh, MD:** Residency research mentor. Currently in UCLA Affiliated Program in Gastroenterology.
- 2005-2007 **Eduard Huang, MD:** Residency research mentor. Currently GI research fellow at Brigham and Women's Hospital.
- 2006-2007 **Benjamin Weinberg, MD:** Fellowship research mentor. Currently in private practice in Southern California.
- 2006-2008 **Amy Strickland, MD:** Residency research mentor. Currently in Loma Linda GI Fellowship training program.
- 2005-2007 **Matthew Solomon, MD, PhD:** Medical School and Residency research mentor. Completed PhD in Health Services at RAND. Currently cardiology fellow at Stanford.
- 2006-2008 **Amar Desai, MD:** Fellowship research mentor. Collaborated with UCSF Department of Nephrology to mentor Dr. Desai, who subsequently took a managed care leadership position upon completion of his fellowship.
- 2007-2009 **Michael Chan, MD:** Residency research mentor. Currently GI fellow at U.S.C.
- 2007-2009 **Sundip Karsan, MD:** Residency research mentor. Currently GI Fellow at UCLA.
- 2008-2009 **Omid Shaye, MD:** Fellowship research mentor. Completed a Master's Degree in Health Services Research through the UCLA School of Public Health. Currently in private practice in Southern California.
- 2008-2009 **Temitope Foster, MD:** Fellowship research mentor through the UCLA STAR Program. Joining academic GI faculty in Washington, DC.
- 2009-Present **Nikhil Agarwal, MD:** Postgraduate research mentor. Currently Research Fellow at the Center for Outcomes Research and Education; starting GI Fellowship July 2011.
- 2010 **Janet Yang, MD:** Fellowship research mentor. Currently Senior Fellow in the UCLA GI Fellowship Training Program.
- 2010 **Hank Wang, MD:** Fellowship research mentor. Currently completing a Master's Degree in Health Services Research under NIH Training Grant, and is a current GI Fellow at UCLA.
- 2010 **Shannon Lewis, MD:** Fellowship research mentor. Currently GI Fellow at UCLA.
- 2010 **Navin Paul, MD:** Fellowship research mentor. Currently GI Fellow at UCLA.

## HONORS AND AWARDS

- 1994 **Golden Key** National Honors Society, Tufts University
- 1995 **New York Medical College** Freshman Research Fellowship
- 1997 **Alpha Omega Alpha** Honors Medical Society, Iota Chapter
- 1999 **Leo G. Rigler Award** for academic achievement, presented to “Intern of the Year” at Cedars-Sinai Medical Center
- 2000 **Solomon Scholars Research Award** for outstanding original research performed during training at a UCLA residency program
- 2001 **Solomon Scholars Research Award**
- 2001 **Rubenstein Award** for excellence in resident research at Cedars-Sinai Medical Center
- 2001 **American College of Physicians-American Society of Internal Medicine** Regional Associates Research Competition - First Place
- 2001 **American Gastroenterological Association** Student Abstract Prize
- 2001 **Gastroenterology Research Group** Student Abstract Award
- 2002 **American College of Gastroenterology and Canadian Association of Gastroenterology** Twelfth Annual North American Conference of Gastroenterology Fellows (NACGF) – Outstanding Research Prize
- 2002 **Center for Ulcer Research and Education (CURE)** annual meeting distinguished abstract
- 2002 **American Society of Gastrointestinal Endoscopy** Young Investigators’ Conference in Digestive Diseases selected research abstract
- 2002 **Gastroenterology Research Group and American Gastroenterological Association** Fellow Abstract Prize
- 2003 **American College of Gastroenterology and Canadian Association of Gastroenterology** Thirteenth Annual North American Conference of Gastroenterology Fellows (NACGF) – Outstanding Research Prize
- 2003 **Functional Brain Gut Research Group** Young Investigators’ Forum outstanding research award
- 2003 **American College of Gastroenterology/AstraZeneca** Senior Fellow Award
- 2003 **Janssen Research Excellence in Gastroenterology and Liver (REGAL)** Award
- 2003 **American College of Gastroenterology and Canadian Association of Gastroenterology** Fourteenth Annual North American Conference of Gastroenterology Fellows (NACGF) selected research abstract.
- 2004 **CURE Named New Investigator Award**
- 2004 **Functional Brain Gut Research Group** Young Investigators’ Forum selected research abstract
- 2004 **American Gastroenterological Association** Distinguished Plenary Abstract (Digestive Disease Week 2004)
- 2004 **VA HSR&D** Research Career Development Award
- 2004 **AstraZeneca Emerging Leaders in Gastroenterology Award**
- 2005 Named to National Register’s **Whose Who List of Medical Professionals®**
- 2005 Named to Marquis’ **Who's Who in Medicine and Healthcare®**
- 2005 **AGA/FDHN** Outcome Research Award
- 2005 **ACG** Annual Meeting **Presidential Poster Award**

- 2005 **UCLA Department of Medicine** Research Day – First Place Award
- 2006 **CURE 2006 Annual Research Meeting** – Distinguished Research Award
- 2006 **UCLA Department of Medicine** Research Day – Plenary Abstract Speaker
- 2007 **American Gastroenterological Association** Distinguished Plenary Abstract (Digestive Disease Week 2007, Washington DC)
- 2007 **International Foundation for Functional Gastrointestinal Disorders (IFFGD)** Distinguished Clinical Investigator Award
- 2007 Recognized by **Annals of Internal Medicine** as a top 10% quality reviewer for 2006.
- 2008 **American Gastroenterological Association** Clinical Plenary Abstract (Digestive Disease Week, 2008, San Diego, CA)
- 2008 Recognized by **Annals of Internal Medicine** as top 10% quality reviewer for 2007.
- 2008 **“Breath of Fresh Air Award”** from the UCLA Fellowship Program in Gastroenterology – Annual award to a faculty member demonstrating enthusiasm and novelty in teaching.
- 2008 Appointed as a **Fellow** of the **American College of Gastroenterology (FACG)**
- 2009 VA Health Services Research and Development (HSR&D) National Meeting Plenary Abstract (Baltimore, MD)
- 2009 Recognized by **Alimentary Pharmacology and Therapeutics** as a top 10% quality reviewer for 2008.
- 2008 Appointed to United States **Food and Drug Administration (FDA)** Gastroenterology Field Advisory Board
- 2009 One of 8 “Key Leaders” in Gastroenterology to receive the **American College of Gastroenterology** Leadership Training Award.
- 2009 Recognized by **Annals of Internal Medicine** as top 10% quality reviewer for 2008.
- 2010 Recognized by **Annals of Internal Medicine** as top 10% quality reviewer for 2009.
- 2011 Selected to present in **Presidential Plenary Session** for Digestive Disease Week, 2011

## RESEARCH GRANTS

### INACTIVE GRANTS

1. **NIH Training Grant Award DK-07180** 7/1/02 – 6/30/04  
 “Cost Effectiveness of Diagnostic Tests in Irritable Bowel Syndrome”  
 \$141,000  
 Principal Investigator  
  
 The major goals of this project were to estimate the cost-effectiveness of sequential diagnostic testing in irritable bowel syndrome.
2. **Janssen / Eisai Pharmaceutica Investigator Initiated Research Grant** 6/1/04 – 12/1/04  
 “The cost-effectiveness of intravenous *versus* oral proton pump inhibitor therapy in the management of peptic ulcer hemorrhage: a decision analysis.”  
 \$35,999  
 Principal Investigator  
  
 This project measured the potential cost-effectiveness of intravenous *versus* oral proton pump inhibitor therapy in the post-hemostasis management of high-risk peptic ulcer hemorrhage. Measurements were derived from a computerized decision analysis.
3. **TAP Pharmaceutical Investigator Initiated Research Grant** 6/1/04 – 10/31/04  
 “Comparing rates of dyspepsia in competing NSAID-based strategies for chronic pain disorders: a systematic review and meta-analysis of clinical trial data.”  
 \$22,260  
 Principal Investigator  
  
 This project was a meta-analysis to compare rates of dyspepsia in three competing NSAID based strategies: (1) non-selective NSAID alone, (2) non-selective NSAID + proton pump inhibitor, and (3) cox-2 selective inhibitor alone.
4. **CURE Named New Investigator Award** 7/1/04 – 6/30/05  
 “Health-Related Quality of Life in Irritable Bowel Syndrome”  
 \$50,000  
 Principal Investigator
5. **CURE Pilot and Feasibility Research Award** 7/1/04 – 6/30/05  
 “Measuring the Reliability of a Concise Extraintestinal Symptom Questionnaire in Irritable Bowel Syndrome”  
 \$17,550  
 Principal Investigator
6. **Johnson and Johnson / Ethicon Investigator Initiated Research Grant** 9/1/05 – 1/31/06  
 “The budget impact of screening for esophageal varices with capsule endoscopy.”  
 \$55,579  
 Principal Investigator
7. **Amgen Pharmaceuticals, Investigator Initiated Research Grant** 11/1/06 – 12/31/06  
 “The Effect of Proposed Changes in Reimbursement for Dialysis Services on Small Dialysis Organizations: A Pilot Study”  
 \$95,000  
 Principal Investigator
8. **Amgen Pharmaceuticals, Investigator Initiated Research Grant** 11/1/05 – 12/31/06

“The cost-effectiveness of competing immunomodulatory therapies in psoriasis”  
 \$56,000  
 Principal Investigator

9. **Amgen Pharmaceuticals, Investigator Initiated Research Grant** 11/1/05 – 12/31/06

“The impact of chronic kidney disease on health related quality of life: a systematic review and quantitative assessment.”  
 \$76,650  
 Principal Investigator

10. **American College of Gastroenterology Clinical Research Grant** 7/1/04 – 12/31/06

“Prospective Validation of a Concise Extraintestinal Symptom Questionnaire in Irritable Bowel Syndrome: the IBS-ESQ”  
 \$14,350  
 Principal Investigator

11. **AGA Foundation Outcomes Research Award** 7/1/05 – 12/31/06

10% Effort  
 “The Effectiveness of an Evidence-Based Pharmacy Sentinel System to Increase the Appropriate Use of PPI Co-Therapy in Chronic NSAID Users: A Randomized Controlled Trial.”  
 \$35,000  
 Principal Investigator

12. **Novartis Pharma AG, Investigator Initiated Research Grant** 7/1/05 – 12/31/06

10% Effort  
 “Development and Validation of a Disease-Targeted Health-Related Quality of Life Instrument in Chronic Hepatitis B Infection: The HBQOL v1.0”  
 \$108,350  
 Principal Investigator

The goal of this project is to develop and validate the first disease-targeted measure of health related quality of life in chronic hepatitis B.

13. **VA HSR&D Entry-Level Research Career Development Award RCD 03-179-2** 7/1/04 – 6/30/07 25% Effort

“The Impact of a Model Physician-Patient Relationship in Irritable Bowel Syndrome”  
 \$399,000  
 Principal Investigator

This project tests the effectiveness of a multifactorial intervention aimed at improving the physician-patient relationship *versus* usual care in the management of irritable bowel syndrome.

14. **Novartis Pharmaceutical** 1/1/07 – 7/31-08

5% Effort  
 “A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II/III Study to Evaluate the Efficacy and Safety of Tegaserod and Placebo Given Orally for the Treatment of Opioid Induced Gastrointestinal Dysfunction in Patients with Chronic Non-Cancer Pain.”  
 \$135,793  
 Principal Investigator

15. **AstraZeneca, Investigator Initiated Research Grant** 8/1/06 – 4/31/07  
 10% Effort  
 “Evaluating Provider Knowledge, Attitudes and Beliefs About PPI Therapy in NVUGIH: A National Vignette Survey of Gastroenterologists”  
 \$39,848  
 Principal Investigator

The goal of this project is to measure the current process of care in nonvariceal upper GI hemorrhage, and to understand provider knowledge, attitudes, and beliefs about using PPI therapy for GI bleeding.

16. **Procter and Gamble, Investigator Initiated Research Grant** 8/1/06 – 6/30/07  
 10% Effort  
 “Evaluating Provider Knowledge, Attitudes and Beliefs in Ulcerative Colitis: A National Vignette Survey of Gastroenterologists”  
 \$89,283  
 Principal Investigator

The goal of this project is to measure the current process of care in ulcerative colitis, and to understand provider knowledge, attitudes, and beliefs about using 5-ASA therapy, in particular, in ulcerative colitis.

17. **TAP Pharmaceutical Investigator Initiated Research Grant** 1/1/07 – 8/1/07  
 10% Effort  
 “Evaluating Provider Knowledge, Attitudes and Beliefs in Dyspepsia Management: A National Vignette Survey of Gastroenterologists”  
 \$95,301  
 Principal Investigator

The goal of this project is to measure the current process of care in dyspepsia, and to understand provider knowledge, attitudes, and beliefs about using PPI and H. pylori therapy, in particular, in dyspepsia.

18. **VA HSR&D Career Development Transition Award (CDTA) RCD 03-179-2** 7/1/07 – 6/30/09  
 25% Effort  
 “Reducing Inappropriate Over- and Under-Use of PPI Therapy in NSAID Users”  
 \$238,300  
 Principal Investigator

This project tested the effectiveness of a computer-reminder to improve compliance with guidelines regarding the use of PPI therapy in chronic NSAID users.

19. **1 R24 AT002681 – NCCAM** 2004-2009  
 5% Effort  
 “Mind/Brain/Body Interactions in Stress-Related Disorders”  
 \$781,703 (Annual Direct)  
 Co-Investigator, Health Outcomes Core Co-Director (PI=Emeran Mayer, MD)

The goal of this infrastructure grant is to develop 4 research cores (Health Outcomes, Neuroimaging, Animal Models, Psychophysiology and Pain Assessment) to provide novel, cutting edge expertise and technologies to UCLA investigators interested in the study of mind brain body interactions. After the full build up of the cores, there will be a Pilot and Feasibility program for years 3-5 of the grant with 4 annual awards. These projects will utilize the resources of the cores as well as the expertise of the involved faculty. In addition, a career development program in form of a Named New Investigator award is included, as well as several developmental and public infrastructure components.

20. **Amgen Pharmaceuticals, Investigator Initiated Research Grant** 4/17/06 – 6/31/09  
10% Effort  
“Identifying Best Practices in Dialysis.”  
\$663,000  
Principal Investigator

The goal of this project is to identify practices, policies, and procedures in dialysis facilities that improve survival in patients undergoing dialysis for chronic kidney disease.

21. **Bristol Myers Squibb Virology Fellows Research Training Program** 6/1/08 – 6/31/09  
5% Effort  
“Are high risk individuals being appropriate screening for hepatitis B? A survey of physicians’ knowledge, attitudes, and beliefs of recently updated CDC guidelines, and in-depth evaluation of screening practices in the Veterans’ Affairs Healthcare System”  
\$19,600  
Co-Principal Investigator

The goal of this project is to measure the current process of care in HBV vaccination, and to understand provider knowledge, attitudes, and beliefs about using appropriate use of HBV vaccination in high risk patients.

22. **Takeda Pharmaceuticals, Investigator Initiated Research Grant** 9/1/09 – 8/31/10  
10% Effort  
“IBS Patient Reported Observed Outcomes and Function (PROOF)”  
\$215,000  
Principal Investigator

The goal of this project is to measure patient reported outcomes in IBS using a multi-center online patient registry.

## ACTIVE GRANTS

### 1. VA HSR&D Merit Award

9/1/09 – 8/31/12

“Impact of a Novel Patient Educational Booklet on Achievement of Quality Indicators in Screening Colonoscopy  
 \$560,000  
 Principal Investigator

This is a 12-month, randomized, controlled trial within an integrated VA healthcare network to compare colonoscopy quality in a group of patients exposed to a novel educational booklet vs. a control group not exposed to the booklet. The primary outcome is be photo-documented bowel prep quality. Secondary outcomes include adherence with key quality indicators, including polyp detection and completed examination rates, along with measuring resource utilization and patient satisfaction. We hypothesize that the intervention, which is based on the Health Belief Model, will improve polyp detection and reduce incomplete exams by improving patient preparation for the test. These benefits will occur while reducing the need for repeated examinations, and thus will save costs compared to the usual practice control group.

### 2. U01 NIH/NIAMS AR057936A

“Development and Initial Validation of PROMIS GI Distress Scale”  
 \$350,000 per year for 4 years (2010-2013)  
 Principal Investigator (PI#2 = Dinesh Khanna, MD, MSHS)  
 15% Effort

The Patient-Reported Outcomes Measurement Information System (PROMIS) initiative aims to develop and disseminate core patient-reported items banks across a wide taxonomy of biopsychosocial illness experiences. Although the current PROMIS taxonomy is expansive, it does not yet include items pertaining to gastrointestinal (GI) Distress. Given the high prevalence and incidence of chronic GI disorders, coupled with the over-representation of many chronic GI disorders in women, it is vital that the PROMIS taxonomy expand to include items pertaining to GI Distress – a domain with relevance to a wide range of chronic diseases marked by decrements in health-related quality of life. Our objectives are to first develop a GI Distress domain using the transparent and rigorous standards established by the PROMIS network, and then to test the resulting items in 3 distinct patient populations with GI distress: (1) irritable bowel syndrome (IBS), (2) inflammatory bowel disease (IBD), and (3) systemic sclerosis (Scleroderma; SSc).

### 3. Shire Pharmaceuticals

“Measuring the Process and Outcomes of Care in Colonic Diverticulitis: Development of a Health Services Database”  
 \$228,976  
 Principal Investigator (PI#2 = Dinesh Khanna, MD, MSHS)  
 10% Effort

This study will develop a detailed, longitudinal, health services database of colonic diverticulitis process and outcomes of care. It will be used to calculate the incidence of acute diverticulitis over time in patients found to have diverticulosis on screening colonoscopy, and to develop and validate a clinical risk calculator that accurately predicts future attacks of acute diverticulitis in patients with diverticulosis. It will be further used to describe clinical outcomes of acute diverticulitis attacks in the Veteran Affairs health system, including length of stay, surger, transfusion requirements, and mortality. We will use the database to compare clinical and resource utilization outcomes over time between patients with diverticulitis vs. age and sex-matched controls.

## **ADDITIONAL ONGOING UNFUNDED RESEARCH STUDIES**

1. Pre-endoscopic process-outcome links in GI bleeding in the VA. Spiegel B, Singh I, Huang E, Karsan S.
2. Balancing cardiovascular and GI outcomes with NSAID therapy: an updated analysis including clopidogrel, aspirin, coxibs, and PPI therapy
3. Does Combat Exposure Predict a Diagnosis of Ulcerative Colitis? A Case-Control Study of United States Veterans. Spiegel B, Talley J, Gupta G.
4. Predictors of no-shows for scheduled colonoscopy in the VA System. Spiegel B, Shekelle P, Talley J, Agarwal N, Poysofion P, Cordasco C.
5. Development of a nomogram for expected allocation in randomized controlled trials. Paul N, Karsan S, Spiegel B.
6. The Cost-Utility of Screening for Celiac Disease in Patients with Unexplained Aminotransferase Elevations. Lewis S, Poysofion P, Spiegel B.
7. Cost-effectiveness of competing treatment for hepatic encephalopathy. Paul N, Spiegel B.
8. Diagnostic Yield of Endoscopy for Weight Loss: Results of a Comparative Cohort Study vs. Non-Weight Loss Controls. Ho A, Snyder B, Poysofion P, Spiegel B.

## LECTURES AND PRESENTATIONS

### INTRAMURAL / LOCAL INVITED PRESENTATIONS

1. Center for Ulcer Research and Education (CURE) annual research meeting. Distinguished clinical abstract oral presentation – *The cost-effectiveness of COX-2 inhibitors in the management of chronic arthritis*, 2002.
2. UCLA Division of Digestive Diseases Grand Rounds – *Health-related quality of life in Gastroenterology: a primer for the dyspeptic skeptic*, 2002.
3. UCLA Division of Digestive Diseases Grand Rounds – *H. pylori eradication for nonulcer dyspepsia: is it worth our time?*, 2002.
4. UCLA Neuroenteric Diseases Symposium, Los Angeles, California – *The health economics of functional gastrointestinal disorders*, 2002.
5. UCLA Affiliated Program in Gastroenterology Fellows' Conference – *Making decisions in life and in Gastroenterology: a primer on decision analysis and cost-effectiveness analysis*, 2002.
6. UCLA Division of Digestive Diseases Grand Rounds – *Iatrogenic Imperfecta and other plagues of the endoscopy suite*, 2002.
7. UCLA-Olive View Medical Center Internal Medicine Residents' Conference – *Acute upper gastrointestinal hemorrhage*, 2002.
8. VA-Greater Los Angeles Medical Center Residents' Conference – *Polyp-induced dyspepsia and other iatrogenic maladies of the GI tract*, 2002.
9. UCLA Affiliated Program in Gastroenterology Fellows' Conference – *How to give an effective talk using Power Point (or, why animation should be left for Saturday mornings)*, 2003.
10. UCLA Division of Digestive Diseases Grand Rounds – *Preventing Polyps and Beating Barrett's with Mister Markov*, 2003.
11. VA-Greater Los Angeles Healthcare System Department of Psychology Grand Rounds – *Measuring Patient Preferences for Economic Analyses*.
12. UCLA Division of Digestive Diseases Grand Rounds – *Does an Aspirin a Day Keep the Polyps Away?* 2003.
13. Cedars-Sinai Division of Gastroenterology Fellows' Conference – *Beating Barrett's with Mister Markov*, 2003.
14. UCLA-Olive View Medical Center Internal Medicine Grand Rounds – *Healthcare Decision Making – A Primer on Decision Analysis and Cost-Effectiveness Analysis*, 2003.
15. University of Michigan Clinical Conference – *Culling the wheat from the chaff in irritable bowel syndrome*, 2004.
16. Harbor-UCLA Medical Center GI Grand Rounds – *Culling the wheat from the chaff in irritable bowel syndrome*, 2004.
17. UCLA-VA Center for Ulcer Research and Education (CURE) Named New Investigator presentation – *Development and Validation of the Irritable Bowel Syndrome Extraintestinal Symptom Questionnaire (IBS-ESQ)*, 2004
18. UCLA-VA Center for Ulcer Research Education annual research meeting – *Invited research presentation. Culling the Wheat from the Chaff in Irritable Bowel Syndrome*, 2004
19. UCLA Center for Neurovisceral Sciences and Women's Health Research Symposium – *An overview of health services research in functional bowel disorders*, 2004.
20. UCLA Affiliated Program in Gastroenterology Fellows' Conference – *How to present without looking stupid: a primer on giving talks and making slides*, 2004

21. Sepulveda VA Medical Grand Rounds – *Culling the wheat from the chaff in irritable bowel syndrome*, 2004
22. UCLA Affiliated Program in Gastroenterology Fellows' Conference – *Health services research highlights from DDW 2004*, 2004
23. VA-Greater Los Angeles Healthcare System Department of Medicine Grand Rounds – *Culling the wheat from the chaff in irritable bowel syndrome*, 2004
24. VA-Greater Los Angeles Healthcare System Department of Medicine Resident's Conference – *A practical approach to managing dyspepsia*, 2004
25. VA-Greater Los Angeles Healthcare System Department of Medicine Resident's Conference – *Surveillance of colonic polyps: which to follow and how?* 2004
26. Providence Holy Cross Medical Center – *Culling the wheat from the chaff in irritable bowel syndrome*, 2004.
27. VA-Los Angeles Outpatient Clinic Department of Medicine Grand Rounds – *Culling the wheat from the chaff in irritable bowel syndrome*, 2004
28. UCLA Medical Student Internal Medicine Clerkship Lecture – *Upper gastrointestinal tract hemorrhage*, 2005
29. UCLA Medical Student Internal Medicine Clerkship Lecture – *A practical approach to jaundice*, 2005.
30. UCLA Management of Barrett's Esophagus Symposium. *Beating Barrett's with Mr. Markov: cost-effectiveness considerations in screening and surveillance*, 2004
31. Center for Neurovisceral Sciences and Women's Health Functional Gastrointestinal Disorders and Co-Morbid Conditions Symposium – *Health related quality of life in functional GI disorders*, 2005
32. UCLA GI Update 2005: Gastroenterology and Hepatology for the Primary Care Physician. *GERD: Endoscopic therapy*, 2005
33. VA-Los Angeles Outpatient Clinic Department of Medicine Grand Rounds *Surveillance of colonic polyps: which to follow and how?* 2004
34. UCLA GI Nursing Symposium. *GERD: Endoscopic therapy*, 2005.
35. UCLA-VA Center for Ulcer Research Education annual research meeting – Invited research presentation. *The impact of somatization on gastrointestinal healthcare resource use in irritable bowel syndrome*, 2005
36. UCLA Division of Digestive Diseases Clinical Conference – *How to use health related quality of life in the management of irritable bowel syndrome*, 2005
37. UCLA Affiliated Program in Gastroenterology Fellows' Conference – *50 Vignettes from the GI Board Examination – Part I*, 2005
38. UCLA Affiliated Program in Gastroenterology Fellows' Conference – *50 Vignettes from the GI Board Examination – Part II*, 2005
39. UCLA/CURE Enrichment Lecture – *Health related quality of life in irritable bowel syndrome*, 2005
40. VA-Greater Los Angeles Healthcare System Department of Medicine Grand Rounds – *Culling the wheat from the chaff in irritable bowel syndrome*, 2005
41. VA-Greater Los Angeles Healthcare System Department of Medicine Grand Rounds – *The four questions approach to GI bleeding*, 2005
42. UCLA Affiliated Program in Gastroenterology Fellows' Conference – *20 Questions about randomized controlled trials*, 2005
43. VA-Greater Los Angeles Healthcare System Department of Medicine Grand Rounds – *An evidence-*

*based approach to managing dyspepsia, 2005*

44. UCLA Affiliated Program in Gastroenterology Fellows' Conference – *Diagnostic testing in IBS and Chronic Constipation, 2006.*
45. UCLA Affiliated Program in Gastroenterology Fellows' Conference – *Screening for Esophageal Varices in Cirrhosis, 2006.*
46. UCLA GI Symposium Update 2006: Gastrointestinal Cancers. *Barrett's Esophagus: Overview / Overdone? 2006*
47. UCLA Department of Medicine Grand Rounds – *Culling the Wheat from the Chaff in Irritable Bowel Syndrome, 2006*
48. UCLA Affiliated Program in Gastroenterology Fellows' Conference – *Vignettes from the GI Board Examination – Part I, 2006*
49. UCLA Affiliated Program in Gastroenterology Fellows' Conference – *Vignettes from the GI Board Examination – Part II, 2006*
50. UCLA Affiliated Program in Gastroenterology Fellows' Conference – *Vignettes from the GI Board Examination – Part III, 2006*
51. UCLA Affiliated Program in Gastroenterology Fellows' Conference – *Vignettes from the GI Board Examination – Part IV, 2006*
52. UCLA Affiliated Program in Gastroenterology Fellows' Conference – *Introduction to Health Related Quality of Life Measurement, 2006*
53. UCLA Department of Medicine Internal Medicine Board Review Course – *Board Review for Gastroenterology, 2006*
54. West Los Angeles VA Department of Medicine Internal Medicine Board Review Series – *Board Review for Gastroenterology, 2006*
55. UCLA Affiliated Program in Gastroenterology Fellows' Conference – *A Primer on Giving Talks and Making Slides, 2006*
56. UCLA Affiliated Program in Gastroenterology Fellows' Conference – *An Evidence-Based Approach to Dyspepsia Management, 2006*
57. VA-Greater Los Angeles Healthcare System Department of Medicine Resident's Conference – *The four question approach to GI bleeding, 2006*
58. UCLA Affiliated Program in Gastroenterology Fellows' Conference – *NSAID Gastropathy in 2006, An Update, 2006*
59. VA-Greater Los Angeles Healthcare System Department of Medicine Resident's Conference – *Barrett's Esophagus, 2006*
60. VA-Greater Los Angeles Healthcare System Department of Medicine Resident's Conference – *NSAID Gastropathy, 2006*
61. UCLA Department of Medicine Research Day **Plenary Invited Speaker** – *Culling the Wheat from the Chaff in Irritable Bowel Syndrome, 2006*
62. UCLA Second Year Medical Student Lecture – *Acid Reflux and Its Consequences, 2006*
63. UCLA Second Year Medical Student Lecture – *Evidence-Based Approach to GI Diseases, 2006*
64. VA-Greater Los Angeles Healthcare System Department of Medicine Resident's Conference – *Screening for Varices in Cirrhosis, 2006*
65. UCLA Affiliated Program in Gastroenterology Fellows' Conference – *Vignettes from the GI Board Examination – Part I, June 2007*
66. UCLA Affiliated Program in Gastroenterology Fellows' Conference – *Vignettes from the GI Board*

*Examination – Part II, June 2007*

67. UCLA Affiliated Program in Gastroenterology Fellows' Conference – *Vignettes from the GI Board Examination – Part III, June 2007*
68. UCLA Affiliated Program in Gastroenterology Fellows' Conference – *Vignettes from the GI Board Examination – Part IV, June 2007*
69. UCLA Affiliated Program in Gastroenterology Fellows' Conference – *A Primer on Giving Talks and Making Slides, July 2007*
70. UCLA Medical Resident's Noon Conference – *Dyspepsia Management, July 2007*
71. UCLA Medical Resident's Journal Club Preceptor – *PPIs and Community Acquired Pneumonia, July 2007*
72. VA Greater Los Angeles Nursing CME Conference – *Gastrointestinal Bleeding, 2007*
73. VA-Greater Los Angeles Healthcare System Department of Medicine **Grand Rounds** – *Acid Reflux and its consequences, 2007*
74. Cedars-Sinai Medical Center Department of Medicine **Grand Rounds** – *Acid Reflux and its consequences, 2008*
75. Ronald Reagan UCLA Department of Medicine **Grand Rounds** – *Acid Reflux and its consequences, 2008*
76. UCLA Medical Resident's Noon Conference – *GI Board Review, 2008*
77. UCLA Training Program in Digestive Diseases Fellows' Conference – *GI Consult Axioms for Success, 2008*
78. UCLA Training Program in Digestive Diseases Fellows' Conference – *The Four Question Approach to GI Bleeding, 2008*
79. UCLA Training Program in Digestive Diseases Fellows' Conference – *Screening for Celiac Sprue in IBS: When, Why, and How?, 2009*
80. UCLA Medical Resident's Noon Conference – *The Four Question Approach to GI Bleeding, 2009*
81. UCLA Training Program in Digestive Diseases Fellows' Conference – *Introduction to Health Related Quality of Life Assessment, 2009*
82. Harbor-UCLA Department of Medicine **Grand Rounds** – *Acid Reflux and its Consequences, 2009*
83. UCLA Training Program in Digestive Diseases Fellows' Conference – *The Four Question Approach to GI Bleeding, 2009*
84. UCLA Department of Medicine Research Day **Plenary Invited Speaker** – *Quality of care in colon cancer screening, 2009*
85. UCLA Medical Resident's Noon Conference, *How to Work Effectively on a Consult Service, 2009.*
86. UCLA Medical Resident's Noon Conference, *The Four Question Approach to GI Bleeding, 2010.*
87. Cedars-Sinai Medical Center Department of Medicine **Grand Rounds** – *The Four Question Approach to GI Bleeding, 2010*
88. UCLA Combined Sub-Specialty Fellow Conference – *How to be a great sub-specialist, 2010*
89. UCLA Department of Medicine **Grand Rounds** – *Quality of care in colon cancer screening, 2010*
90. Kaiser Sunset Department of Gastroenterology **Grand Rounds** – *Quality of care in colon cancer screening, 2011*

## NATIONAL / INTERNATIONAL INVITED PRESENTATIONS

1. Digestive Disease Week 2001, Atlanta, Georgia. AGA Topic Forum presentation - *Dyspepsia management in primary care: a reappraisal of competing strategies.*
2. Methodologies in Healthcare Outcomes in Gastroenterology 2001, Miami, Florida. *Dyspepsia management in primary care: a reappraisal of competing strategies.*
3. Methodologies in Healthcare Outcomes in Gastroenterology 2001, Miami, Florida. *The cost-effectiveness of COX-2 inhibitors in the management of chronic arthritis.*
4. ASGE Young Investigators' Conference in Digestive Diseases 2002, Indian Wells, California. *Is universal screening endoscopy cost-effective in cirrhosis?*
5. Digestive Disease Week 2002, San Francisco, California. ASGE topic forum – *Is universal screening endoscopy cost-effective in cirrhosis?*
6. Digestive Disease Week 2002, San Francisco, California. AGA topic forum – *The cost-effectiveness of COX-2 inhibitors in the management of chronic arthritis.*
7. American College of Rheumatology 2002 annual scientific meeting New Orleans, LA. Clinical epidemiology symposium invited presentation – *Using decision analysis to aid clinical choices: case study with COX-2 inhibitors.*
8. Veterans' Administration Health Services Research and Development National Meeting, 2003, Washington, DC. *The cost-effectiveness of COX-2 inhibitors in the management of chronic arthritis.*
9. First Annual Functional Brain Gut Research Group Young Investigators' Forum, 2002, Scottsdale, Arizona. *Clinical determinants of health related quality of life in irritable bowel syndrome.*
10. Research Excellence in Gastroenterology and Hepatology (REGAL) Research Conference, 2003, Scottsdale, Arizona. *The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.*
11. Digestive Disease Week 2004, New Orleans, LA. **AGA Distinguished Abstract Plenary Session** – *Is it worth testing for celiac sprue in irritable bowel syndrome? A cost-effectiveness analysis.*
12. AGA Functional Bowel Diseases Symposium, DDW 2004, New Orleans, LA. *Why it matters to know your patients' quality of life in IBS.*
13. Methodologies in Healthcare Outcomes in Gastroenterology 2004, San Francisco, California. *How to Perform a Cost-Effectiveness Analysis.*
14. Methodologies in Healthcare Outcomes in Gastroenterology 2004, San Francisco, California. *Advanced Methods in Cost-Effectiveness Analysis.*
15. AGA Advances in the Management of Irritable Bowel Syndrome Symposium, Los Angeles, California. *Why it matters to know your patients' quality of life in IBS, 2005*
16. 6<sup>th</sup> International Symposium on Functional Gastrointestinal Disorders, Milwaukee, WI. *Understanding quality of life impact of illness, 2005*
17. Digestive Disease Week 2005, Chicago, IL. AGA Topic Forum – *Comparing rates of dyspepsia with coxibs versus NSAID+PPI: A Systematic Review and Meta-Analysis of Clinical Trial Data.*
18. Digestive Disease Week 2005, Chicago, IL. AGA Topic Forum – *The impact of somatization on the use of gastrointestinal healthcare resources in irritable bowel syndrome.*
19. Southern California Gastroenterology Society Post-DDW Conference, La Costa, Calif. – *Controversies of the Stomach: H. pylori and Dyspepsia, 2005*
20. Emerging Leaders in Gastroenterology Conference 2005, Stockholm, Sweden. *The Effectiveness of a Model Physician-Patient Relationship in Veterans with Irritable Bowel Syndrome, 2005*
21. University of Manitoba Visiting Professorship Lecture. *Culling the Wheat from the Chaff in Irritable Bowel Syndrome, 2005.*

22. Methodologies in Healthcare Outcomes in Gastroenterology 2005, Phoenix, AZ. *How to Perform a Cost-Effectiveness Analysis.*
23. Methodologies in Healthcare Outcomes in Gastroenterology 2005, Phoenix, AZ. *Advanced Methods in Cost-Effectiveness Analysis.*
24. Methodologies in Healthcare Outcomes in Gastroenterology 2005, Phoenix, AZ. *Introduction to Quality of Life Measurement.*
25. Veterans' Administration Health Services Research and Development National Meeting, 2006, Washington, DC. *The Effectiveness of a Model Physician-Patient Relationship in Veterans with Irritable Bowel Syndrome.*
26. Digestive Disease Week (DDW) 2006 **Post Graduate Course**, Los Angeles, Calif – *Screening for Esophageal Varices in Cirrhosis: Is it Ever Worth it?*
27. Digestive Disease Week (DDW) 2006 AGA Clinical Symposium, Los Angeles, Calif – *How to use Health Related Quality of Life to Monitor Patient Progress.*
28. Digestive Disease Week (DDW) 2006 AGA “Meet the Professor” Lecture, Los Angeles, California – *Quality of Life Measurement*
29. Digestive Disease Week (DDW) 2006 AGA Topic Forum – *The effectiveness of a model physician-patient relationship in irritable bowel syndrome: a randomized controlled trial.*
30. Digestive Disease Week (DDW) 2006 AGA Topic Forum – *Is irritable bowel syndrome a diagnosis of exclusion? A survey of primary care providers, gastroenterologists, and IBS experts.*
31. Digestive Disease Week (DDW) 2006 ASGE Topic Forum – *The managed care budget impact of capsule endoscopy for variceal screening.*
32. Southern California Gastroenterology Society Post-DDW Conference, Newport Beach, Calif. – *Controversies in functional GI: diagnosis, epidemiology, and non-pharmacological treatments, 2006*
33. Methodologies in Healthcare Outcomes in Gastroenterology 2006, Denver, CO. *How to Perform a Cost-Effectiveness Analysis.*
34. Methodologies in Healthcare Outcomes in Gastroenterology 2006, Denver, CO. *Advanced Methods in Cost-Effectiveness Analysis.*
35. Methodologies in Healthcare Outcomes in Gastroenterology 2006, Denver, CO. *Introduction to Quality of Life Measurement.*
36. University of Illinois Visiting Professorship Lecture. *Culling the Wheat from the Chaff in Irritable Bowel Syndrome, 2006.*
37. Case Western University of Manitoba Visiting Professorship Lecture. *Culling the Wheat from the Chaff in Irritable Bowel Syndrome, 2006.*
38. Northwestern University Visiting Professorship Lecture. *Culling the Wheat from the Chaff in Irritable Bowel Syndrome, 2006.*
39. Digestive Disease Week (DDW) 2007, AGA Nonvariceal Upper GI Bleeding Topic Forum, Washington, DC – *Adherence to “best practices” in nonvariceal upper GI hemorrhage (NVUGIH): a national vignette survey of experts versus community providers.*
40. Digestive Disease Week (DDW) 2007, AGA Outcomes in Functional Gastrointestinal Disorders Topic Forum, Washington, DC – *Is Asking “How are you doing” enough to capture health related quality of life (HRQOL) and overall severity in irritable bowel syndrome (IBS)?*
41. Digestive Disease Week (DDW) 2007, AGA NSAID Topic Forum, Washington, DC – *Improving adherence with PPI prescribing guidelines in high-risk NSAID Users: a controlled “before and after” study of an electronic medical reminder.*
42. Digestive Disease Week (DDW) 2007, **AGA Distinguished Abstract Plenary Session**, Washington, DC – *Balancing Cardiovascular and GI Outcomes with Antiplatelet Therapy: A Cost-Effectiveness Analysis of Competing Strategies.*

43. Digestive Disease Week (DDW) 2007, AGA Clinical Symposium, Washington, DC – *Screening for Celiac Sprue in IBS: Why, When and How?*
44. Digestive Disease Week (DDW) 2007, AGA Clinical Symposium, Washington, DC – *Measuring Severity in IBS: Why and How?*
43. Methodologies in Healthcare Outcomes in Gastroenterology 2007, Ft. Lauderdale, FL. *Introduction to pharmacoeconomic analyses.*
44. Methodologies in Healthcare Outcomes in Gastroenterology 2007, Ft. Lauderdale, FL. *Introduction to health related quality of life.*
45. Methodologies in Healthcare Outcomes in Gastroenterology 2007, Ft. Lauderdale, FL. *Introduction to survey development and administration.*
46. Presentation to the United States Food and Drug Administration GI and SEALD groups – *Rome Activities Related to Outcome and Endpoint Validation*, December 2007, Silver Springs, MD.
47. Presentation to the United States Food and Drug Administration GI and SEALD groups – *What Defines Symptom Severity in IBS? Evolving Conceptual Framework*, May 2008, Silver Springs, MD.
48. Digestive Disease Week (DDW) 2008, **AGA Clinical Plenary Session**, San Diego, CA – *Does the first colonoscopy of the day yield more polyps than cases performed later?*
49. Digestive Disease Week (DDW) 2008, AGA Clinical Symposium, San Diego, CA – *Do Frequent Hemoglobin (Hgb) Checks Improve Outcomes in GI Hemorrhage?*
50. Digestive Disease Week (DDW) 2008, AGA Clinical Symposium, San Diego, CA – *Predictors of Work Productivity in Irritable Bowel Syndrome (IBS): Results from the PROOF Cohort*
51. Digestive Disease Week (DDW) 2008, AGA Clinical Symposium, San Diego, CA – *EuroQOL Utilities Demonstrate Excellent Validity and Responsiveness in IBS: Results from the PROOF Cohort*
52. Digestive Disease Week (DDW) 2008, AGA Clinical Symposium, San Diego, CA – *Could Natural Orifice Transluminal Endoscopic Surgery (NOTES) Ever be Cost Effective vs Laparoscopy (LAP)? A Hypothesis Generating Decision Analysis*
53. Digestive Disease Week (DDW) 2008, AGA Clinical Symposium, San Diego, CA – *Putting it all together – evidence based approach to dyspepsia management.*
54. University of Manitoba Department of Gastroenterology, Update in Endoscopy, 2008 – *Evidence-Based Approach to Lower Gastrointestinal Tract Hemorrhage.*
55. VA HSR&D National Meeting, 2009, **Plenary Session**, Baltimore, MD – *Impact of a novel patient educational booklet on colonoscopy preparation in veterans.*
56. Rome Foundation Endpoints and Outcomes Conference, 2009, Milwaukee, WI – *Results of the Rome Endpoints Working Group Meta-Analysis.*
57. Rome Foundation Endpoints and Outcomes Conference, 2009, Milwaukee, WI – *Measuring minimally clinically important differences using patient reported outcomes (PROs)*
58. Rome Foundation Endpoints and Outcomes Conference, 2009, Milwaukee, WI – *Health Behaviors, Health Outcomes, and Cost-Effectiveness in IBS*
59. International Foundation for Functional Gastrointestinal Disorders (IFFGD) Conference, 2009, Milwaukee, WI – *Validating Questionnaires for Clinical Practice.*
60. University of Miami Division of Digestive Diseases Visiting Professorship Lecture, 2009, Miami, FL – *Culling the Wheat from the Chaff in Irritable Bowel Syndrome.*
61. Digestive Disease Week (DDW) 2009 AGA Clinical Symposium, Chicago, IL – *Impact of Baseline Severity on the Performance of IBS Clinical Trial Endpoints: Results of the Rome Endpoints Working Group Meta-Analysis*
62. Digestive Disease Week (DDW) 2009 AGA Clinical Symposium, Chicago, IL – *Early Endoscopy Predicts Lower Mortality in Acute Gastrointestinal Hemorrhage*
63. Digestive Disease Week (DDW) 2009 AGA Clinical Symposium, Chicago, IL – *Colonoscopy Yields*

*Fewer Polyps as the Day Progresses Despite Use of Social Influence to Reverse the Trend*

64. Digestive Disease Week (DDW) 2009 AGA Clinical Symposium, Chicago, IL – *Impact of a Novel Patient Educational Booklet on the Quality of Colonoscopy Preparation in Colorectal Cancer Screening*
65. Digestive Disease Week (DDW) 2009 AGA Clinical Symposium, Chicago, IL – *Utility of New Diagnostic Tests in IBS Patients*
66. University of North Carolina at Chapel Hill Division Digestive Diseases Visiting Professorship Lecture, 2009, Chapel Hill, NC – *Culling the Wheat from the Chaff in Irritable Bowel Syndrome.*
67. University of North Carolina at Chapel Hill Division Digestive Diseases Visiting Professorship Lecture, 2009, Chapel Hill, NC – *Introduction to Health Related Quality of Life Measurement.*
68. American College of Gastroenterology 2009 Annual Meeting, San Diego, Calif – *Non-pharmacological approaches to enhancing bowel prep tolerance and quality.*
69. American Gastroenterological Association Clinical Congress, 2010, Las Vegas, NV – *Evidence-Based Approach to Dyspepsia*
70. Digestive Disease Week (DDW) 2010, AGA Clinical Symposium, New Orleans, LA – *Screening for Celiac Disease in IBS: When, How, and Why?*
71. Digestive Disease Week (DDW) 2010, AGA Meet the Professor, New Orleans, LA – *Evidence Based Approach to Diagnostic Testing in IBS*
72. Digestive Disease Week (DDW) 2010, AGA Clinical Symposium, New Orleans, LA – *Characterizing Abdominal Pain Attributes in IBS: Guidance for Study Inclusion Criteria and Outcome Measurement*
73. Digestive Disease Week (DDW) 2010, AGA Clinical Symposium, New Orleans, LA – *Patient-Reported Symptom Relief from Current Therapy is a Robust Marker of Illness Severity in IBS*
74. Digestive Disease Week (DDW) 2010, AGA Clinical Symposium, New Orleans, LA – *The Impact of Elevated INR on Outcomes in GI Hemorrhage*
75. Digestive Disease Week (DDW) 2010, AGA Clinical Symposium, New Orleans, LA – *Impact of a novel educational booklet on bowel preparation in screening colonoscopy*
76. 2010 Joint International Neurogastroenterology and Motility Meeting, Boston, MA – *Advances in trial endpoints in IBS: binary endpoints, PRO guidance, and validity of interim endpoints.*
77. Digestive Disease Week (DDW) 2011, **AGA Postgraduate Course**, Chicago, Il – *An evidence-based approach to managing dyspepsia.*
78. Digestive Disease Week (DDW) 2011, **ASGE Presidential Plenary Session**, Chicago, Il – *Adenomas under the curve (AUC): a new metric that incorporates and extends the adenoma detection rate (ADR)*
79. Digestive Disease Week (DDW) 2011, AGA Clinical Symposium, Chicago, Il – *New endpoints for dyspepsia trials: lessons from IBS.*
80. Digestive Disease Week (DDW) 2011, AGA Clinical Symposium, Chicago, Il – *Developing a PRO in IBS: Lessons learned for what can go wrong and how to fix it.*
81. Digestive Disease Week (DDW) 2011, AGA Clinical Symposium, Chicago, Il – *Clinical Presentation of Acute Diverticulitis: Most Patients Do Not Fulfill the Classic Triad of Pain, Fever, and Leukocytosis.*
82. Digestive Disease Week (DDW) 2011, AGA Clinical Symposium, Chicago, Il – *What diagnostic tests are needed in patients with IBS symptoms?*

## BIBLIOGRAPHY

### RESEARCH PAPERS – PEER REVIEWED

1. **Spiegel BMR**, Vakil NB, Ofman JJ. Endoscopy for acute non-variceal upper gastrointestinal tract hemorrhage: is sooner better? A systematic review. *Archives of Internal Medicine* 2001;161:1393-1404
2. **Spiegel BMR**, Vakil NB, Ofman JJ. Dyspepsia management in primary care: a decision analysis of competing strategies. *Gastroenterology* 2002;122:1270-1285 [with editorial]
3. **Spiegel BMR**, Ofman JJ, Vakil NB. Minimizing recurrent peptic ulcer hemorrhage after endoscopic hemostasis: the cost-effectiveness of competing strategies. *American Journal of Gastroenterology* 2003;98:86-97
4. **Spiegel BMR**, Targownik LE, Karsan HA, Dulai GS, Gralnek IM. Endoscopic screening for esophageal varices in cirrhosis: is it ever cost-effective? *Hepatology* 2003;37:366-77 [with editorial]
5. **Spiegel BMR**, Targownik LE, Dulai GS, Gralnek IM. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. *Annals of Internal Medicine* 2003;138:795-806
6. Targownik LE, Gralnek IM, Dulai GS, **Spiegel BMR**, Oei T, Bernstein CN. Management of acute non-variceal upper gastrointestinal tract hemorrhage: comparison of a U.S. and a Canadian medical center. *Canadian Journal of Gastroenterology* 2003;17:489-95
7. **Spiegel BMR**, DeRosa VP, Gralnek IM, Wang V, Dulai GS. Testing for celiac sprue in diarrhea-predominant irritable bowel syndrome: a cost-effectiveness analysis. *Gastroenterology* 2004;126:1721-32
8. Targownik LE, **Spiegel BM**, Dulai GS, Karsan HA, Gralnek IM. The cost-effectiveness of hepatic pressure gradient monitoring in the prevention of recurrent variceal hemorrhage. *American Journal of Gastroenterology* 2004;99:1306-15
9. **Spiegel BMR**, Targownik LE, DeRosa V, Dulai GS, Gralnek IM, Chiou CF. The quality of published health economic analyses in digestive diseases: a systematic review and quantitative appraisal. *Gastroenterology* 2004;127:403-411
10. **Spiegel BMR**, Gralnek IM, Mayer EB, Bolus R, Dulai GS, Chang L, Naliboff B. Clinical determinants of health-related quality of life in patients with irritable bowel syndrome. *Archives of Internal Medicine* 2004;164:1773-1780
11. Targownik LE, **Spiegel BMR**, Dulai GS, Gralnek IM, Farrell J. Colonic stent vs. emergency surgery for management of acute left-sided malignant colonic obstruction: A decision analysis. *Gastrointestinal Endoscopy* 2004;60:865-74
12. Kanwal F, Dulai GS, **Spiegel BMR**, Yee HF, Gralnek IM. Recipient Characteristics and Post-Liver Transplantation Outcomes Before and After MELD. *Alimentary Pharmacology and Therapeutics* 2005;15;21:169-77
13. Dulai GS, Shekelle P, Jensen DM, **Spiegel BMR**, Chen J, Oh D, Kahn K. Dysplasia and risk of neoplastic progression in a regional Veteran's Administration Barrett's surveillance cohort. *American Journal of Gastroenterology* 2005;100:775-83
14. **Spiegel BMR**, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. The impact of hepatitis C on health related quality of life: a systematic review of the literature. *Hepatology* 2005;41:790-800
15. Karsan HA, Morton SC, Shekelle PG, Suttorp MJ, **Spiegel BMR**, Edelstein MA, Shanman R, Gralnek IM. Combination endoscopic band ligation and sclerotherapy compared with endoscopic band ligation alone for the secondary prophylaxis of esophageal variceal hemorrhage: a meta-analysis. *Digestive Diseases and Sciences* 2005;50:399-406
16. **Spiegel BMR**, Chiou CF, Ofman JJ. Minimizing complications from nonsteroidal anti-inflammatory drugs: the cost-effectiveness of competing strategies in varying risk groups. *Arthritis Care and Research* 2005;15:185-97

17. Bloom M, Barghout V, Kahler K, Bentkover J, Kurth H, Gralnek IM, **Spiegel BMR**. Budget Impact of Tegaserod on a Managed Care Organization Formulary. *American Journal of Managed Care* 2005;11:S27-S34
18. Kanwal F, Gralnek IM, Martin P, Dulai GS, Martin P, **Spiegel BMR**. The cost-effectiveness of competing therapies in the management of chronic infection with hepatitis B virus. *Annals of Internal Medicine* 2005;142:821-31. [Spiegel=Corresponding Author]
19. Tan S, Tillisch K, Bolus R, Olivas T, Naliboff L, Chang L, **Spiegel BMR**, Mayer EA S. Subgrouping of irritable bowel syndrome patients using traditional Chinese medicine symptom classification – a pilot study. *Am J Chin Med.* 2005;33(3):365-79
20. Kanwal F, Gralnek IM, Hays RD, **Spiegel BMR**, Dulai GS, Bozzette S, Asch S. Impact of chronic viral hepatitis on health related quality of life in HIV: results from a nationally representative sample. *American Journal of Gastroenterology.* 2005;100:1984-94
21. **Spiegel BMR**, Kanwal F, Naliboff B, Mayer E. The impact of somatization on gastrointestinal health resource use in irritable bowel syndrome. *American Journal of Gastroenterology* 2005;100:2262-73 [Spiegel=Corresponding Author]
22. **Spiegel BMR**, Chen K, Broder M, Chiou Chiun-Fang. Erythropoietic Growth Factors for the management of treatment-related anemia in hepatitis C: clinical and economic consequences. *Clinical Gastroenterology and Hepatology* 2005;3:1034-42 [Spiegel=Corresponding Author]
23. **Spiegel BMR**, Gralnek IM, Bolus R, Mayer E, Chang L, Dulai GS, Naliboff B. Is a negative colonoscopy associated with improved health-related quality of life or reassurance in irritable bowel syndrome? *Gastrointestinal Endoscopy* 2005;62:892-899
24. **Spiegel BMR**, Farid M, Gralnek IM, Dulai GS, Kanwal F. Comparing rates of dyspepsia with coxib versus NSAID+PPI combination therapy: a systematic review and meta-analysis. *American Journal of Medicine* 2006; 119(5):448.e27-36
25. **Spiegel BMR**, Lim B, Mann N, Dulai GS, Gralnek IM. The cost-effectiveness of intravenous versus oral proton pump inhibitor therapy in the management of peptic ulcer hemorrhage: a cost-effectiveness analysis. *Clinical Gastroenterology and Hepatology* 2006;4:988-997
26. Kanwal F, Farid M, Gralnek IM, Dulai G, Martin P, Chen G, **Spiegel BMR**. Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis. *American Journal of Gastroenterology* 2006;101:2076-89 [Spiegel=Corresponding Author]
27. Gralnek IM, Fennerty B, **Spiegel BMR**. The effectiveness of esomeprazole in erosive esophagitis: a meta-analysis. *Clin Gastroenterol Hepatol.* 2006;4:1452-8
28. **Spiegel BMR**, Bolus R, Han S, Tong M, Esrailian E, Talley J, Tran T, Smith J, Karsan H, Durazo F, Bacon B, Martin P, Younossi Z, Hwa-Ong S, Kanwal F. Development and validation of a disease-targeted health-related quality of life instrument in chronic hepatitis B infection: the HBQOL v1.0. *Hepatology* 2007;46:113-21 [Spiegel=Corresponding Author]
29. **Spiegel BMR**, Schoenfeld P, Naliboff B. Prevalence of suicidal behavior in patients with chronic abdominal pain and irritable bowel syndrome: a systematic review. *Aliment Pharmacol Ther.* 2007;26:183-193.
30. Singh H, Latosinsky S, **Spiegel BM**, Targownik LE. The cost-effectiveness of colonic stenting as a bridge to curative surgery in patients with acute left-sided malignant colonic obstruction: a Canadian perspective. *Can J Gastroenterol.* 2006 ;20:779-85
31. Esrailian E, **Spiegel BMR**, Targownik L, Dulai GS, Gralnek IM. Differences in the management of Crohn's disease among experts and community providers, based on a national survey of sample case vignettes. *Aliment Pharmacol Ther.* 2007;26:1005-18
32. **Spiegel BMR**, Esrailian E, Laine L, Chamberlain M. Clinical relevance of adjuvant chemotherapy in glioblastoma multiforme: a meta-analysis of competing agents. *CNS Drugs* 2007;21:775-87. [Spiegel=Corresponding Author]
33. **Spiegel BMR**, Esrailian E, Eisen G. The budget impact of screening for esophageal varices in cirrhosis *Gastrointestinal Endoscopy* 2007;66:679-92 [Spiegel=Corresponding Author]

34. Huang E, Esrailian E, **Spiegel BMR**. The cost-effectiveness of competing therapies for hepatic encephalopathy: a decision analysis. *Alimentary Pharmacology and Therapeutics*. 2007;26:1147-61 [Spiegel=Corresponding Author]
35. Mayer EA, Bradesi S, Chang L, **Spiegel BMR**, Bueller JA, Naliboff BD. Functional GI disorders: From animal models to drug development. *Gut* 2007
36. Kanwal F, Hoang T, **Spiegel BMR**, Dominitz J, Goetz M, Gifford A, Asch S. Predictors of treatment in patients with chronic hepatitis C virus infection—Role of patient versus non-patient factors. *Hepatology*;46:1741-9 2007
37. World Gastroenterology Organization Advisory Board on Irritable Bowel Syndrome. Systematic review on the management of irritable bowel syndrome in the European Union. *Eur J Gastro Hep* 2007;19:S11-37 [Member of Advisory Board and co-author of consensus document]
38. Desai A, Bolus R, Nissenson A, Bolus S, Solomon M, Khawar O, Gitlin M, Talley J, **Spiegel BMR**. Identifying “best practices” in dialysis care: results of a national survey and cognitive interviews of dialysis stakeholders. *Clinical Journal of the American Society of Nephrology (CJASN)* 2008; Apr 16 [Spiegel=Corresponding Author]
39. **Spiegel BMR**, Strickland A, Naliboff B, Mayer E, Chang L. Predictors of patient-assessed illness severity in irritable bowel syndrome. *American Journal of Gastroenterology* 2008 [Jun 30 – Epub ahead of print] [Spiegel=Corresponding Author]
40. **Spiegel BMR**, Melmed G, Robbins S, Esrailian E. The relationship between biomarkers and health related quality of life in end-stage renal disease: a systematic review. *Clinical Journal of the American Society of Nephrology (CJASN)* 2008; Oct 1 [Epub ahead of print] [Spiegel=Corresponding Author]
41. Esrailian E, Gralnek IM, Jensen D, Laine L, Dulai GS, Eisen G, **Spiegel BMR**. Evaluating the process of care in non-variceal upper gastrointestinal hemorrhage: a national vignette survey of experts vs. community gastroenterologists. *Alimentary Pharmacology & Therapeutics* 2008;28:1199. [Spiegel=Corresponding Author]
42. **Spiegel BMR**, Ho W, Esrailian E, Targan S, Higgins P, Siegel C, Dubinsky M, Melmed G. Controversies in Ulcerative Colitis: A National Survey Comparing Decision-Making of Experts versus Community Gastroenterologists. *Clinical Gastroenterology and Hepatology*. 2008 [Epub ahead of print] [Spiegel=Corresponding Author].
43. Ford AC, Talley NJ, **Spiegel BMR**, Foxx-Orenstein A, Schiller L, Quigley EMM, Moayyedi P. Efficacy of fibre, antispasmodics, and peppermint oil in irritable bowel syndrome: systematic review and meta-analysis. *British Medical Journal*. 2008 13;337.
44. Greengold B, Nyamathi A, Kominski G, Hodge F, Singer M, **Spiegel BMR**. Cost-Effectiveness Analysis of Behavioral Intervention to Improve Vaccination Compliance in Homeless Adults. *Vaccine*. 2008;27:718-25
45. Kanwal F, **Spiegel BMR**, Hays RD, Bolus R, Kim SJ, Gralnek IM. Prospective validation of the short form liver disease quality of life instrument (SF-LDQOL). *Aliment Pharmacol Ther*. 2008;28:1088-101
46. **Spiegel BMR**, Farid M, van Oijen MGH, Laine L, Howden CW, Esrailian E. Adherence to best practice guidelines in dyspepsia: a survey comparing dyspepsia experts, community gastroenterologists, and primary care providers. *Alimentary Pharmacology and Therapeutics* 2009;29:871-81[Spiegel=Corresponding Author]
47. Desai A, Bolus R, Nissenson A, Chertow GM, Bolus S, Solomon M, Khawar O, Talley J, **Spiegel BMR**. Is there “cherry picking” in the ESRD program? Perceptions from a dialysis provider survey. *Clinical Journal of the American Society of Nephrology (CJASN)* 2009;4:772-7 [Spiegel=Corresponding Author]
48. Kanwal F, Gralnek IM, Bolus R, Kim SJ, **Spiegel BMR**. Health Related Quality of Life Predicts Mortality in Patients awaiting Liver Transplantation. *Clinical Gastroenterology and Hepatology* 2009 [Epub ahead of print] [Spiegel=Corresponding Author]
49. Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis. Ford AC, Chey WD, Talley NJ, Malhotra A, **Spiegel BM**, Moayyedi P. *Arch Intern Med*. 2009 Apr 13;169:651-8

50. **Spiegel BM**, Harris L, Lucak S, Mayer E, Naliboff B, Bolus R, Esrailian E, Chey WD, Lembo A, Karsan H, Tillisch K, Dulai G, Talley J, Chang L. Developing valid and reliable health utilities in irritable bowel syndrome: results from the IBS PROOF cohort. *American Journal of Gastroenterology* 2009 [Epub ahead of print] [Spiegel=Corresponding Author]
51. Desai A, Farid M, Singh I, van Oijen MGH, Esrailian E, Solomon MD, **Spiegel BM**. The relationship between laboratory-based outcomes and mortality in end-stage renal disease: a systematic review. *Hemodialysis International* 2009[Epub ahead of print] [Spiegel=Corresponding Author]
52. Ford AC, **Spiegel BMR** Talley NJ, Moayyedi P. Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: Systematic Review and Meta-analysis. *Clinical Gastroenterology and Hepatology* July 2009 [Epub ahead of print]
53. Chan M; Cohen H; **Spiegel BM**. Colonoscopy yields fewer polyps as the day progresses: Experience in a Veteran Administration teaching hospital. *Clinical Gastroenterology and Hepatology* [Epub ahead of print] [Spiegel=Corresponding Author]
54. **Spiegel BM**, Camilleri M, Bolus R, Andresen V, Chey WD, Fehnel S, Mangel A, Talley NJ, Whiehead WE. Psychometric evaluation of endpoints in IBS randomized controlled trials: a Rome Foundation Working Group report. *Gastroenterology* [Epub ahead of print] [Spiegel=Corresponding Author]
55. **Spiegel BM**, Bolus R, Harris LA, Lucak S, Naliboff B, Esrailian E, Chey WD, Lembo A, Karsan H, Tillisch K, Talley J, Mayer E, Chang L. Measuring IBS patient reported outcomes with an abdominal pain numeric rating scale: results from the PROOF cohort. *Alimentary Pharmacology and Therapeutics*. [Epub ahead of print] [Spiegel=Corresponding Author]
56. Weinberg B, **Spiegel BM**, Tomlinson J, Farrel J. Asymptomatic Pancreatic cysts: maximizing survival and quality of life using Markov-based clinical nomograms. *Gastroenterology*. [Epub ahead of print] [Spiegel=Corresponding Author]
57. **Spiegel BM**, Farid M, Esrailian E, Talley J, Chang L. Is irritable bowel syndrome a diagnosis of exclusion? A survey of primary care providers, gastroenterologists, and IBS experts. Manuscript in press at *American Journal of Gastroenterology*. [Spiegel=Corresponding Author]
58. **Spiegel BM**, Bolus R, Desai AA, Zagar P, Parker T, Moran J, Bolus S, Solomon MD, Khawar O, Gitlin M, Talley J, Nissenson A. Dialysis practices that distinguish top vs. bottom performing facilities by hemoglobin outcomes. *Am J Kidney Dis*. 2010 May 19. [Epub ahead of print] [Spiegel=Corresponding Author]
59. Melmed GY, **Spiegel BM**, Bressler B, Cheifetz AS, Devlin SM, Harrell LE, Irving PM, Jones J, Kaplan GG, Kozuch PL, Velayos FS, Baidoo L, Sparrow MP, Siegel CA. The appropriateness of concomitant immunomodulators and anti-TNF agents for Crohn's disease: one size does not fit all. *Clin Gastroenterol Hepatol*. 2010 May 5. [Epub ahead of print]
60. Kanwal F, Kramer J, Asch SM, El-Serag H, **Spiegel BM**, Edmundowicz S, Sanyal AJ, Dominitz JA, McQuaid KR, Martin P, Keeffe EB, Friedman LS, Ho SB, Durazo F, Bacon BR. An explicit quality indicator set for measurement of quality of care in patients with cirrhosis. *Clin Gastroenterol Hepatol*. 2010 Apr 10. [Epub ahead of print]
61. **Spiegel BM**, Farid M, Esrailian E, Talley J, Chang L. Is irritable bowel syndrome a diagnosis of exclusion? A survey of primary care providers, gastroenterologists, and IBS experts. *Am J Gastroenterol*. 2010 Apr;105(4):848-58. Epub 2010 Mar 2. [Spiegel=Corresponding Author]
62. Barkun AN, Bardou M, Kuipers EJ, Sung J, Hunt RH, Martel M, Sinclair P; International Consensus Upper Gastrointestinal Bleeding Conference Group. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. *Ann Intern Med*. 2010 Jan 19;152(2):101-13. [Spiegel=Contributing member of consensus panel]
63. Kanwal F, Barkun A, Gralnek IM, Asch SM, Kuipers EJ, Bardou M, Sung J, Enns R, Agreus L, Armstrong D, **Spiegel BM**. Measuring quality of care in patients with nonvariceal upper gastrointestinal hemorrhage: development of an explicit quality indicator set. *Am J Gastroenterol* 2010;105:1710-8 [Spiegel=Corresponding Author]
64. Adeyemo MA, **Spiegel BM**, Chang L. Meta-analysis: do irritable bowel syndrome symptoms vary between men and women? *Aliment Pharmacol Ther* 2010 [Epub ahead of print]

65. **Spiegel BM**, Roberts L, Mody R, Harding G, Kothari-Talwar S, Kahrilas PJ, Camilleri ML, Dabbous O, Revicki DA. The Development and validation of a Nocturnal Gastro-oesophageal Reflux Disease Symptom Severity and Impact Questionnaire for adults. *Aliment Pharmacol Ther* 2010;32:591-602 [Spiegel=Corresponding Author]
66. **Spiegel BM**, Bolus R, Desai AA, Zagar P, Parker T, Moran J, Bolus S, Solomon MD, Khawar O, Gitlin M, Talley J, Nissenson A. Dialysis practices that distinguish facilities with below versus above-average mortality. *Am J Kidney Dis*. 2010;56:86-94 [Spiegel=Corresponding Author]
67. Melmed GY, **Spiegel BM**, Bressler B, Cheifetz AS, Devlin SM, Harrell LE, Irving PM, Jones J, Kaplan GG, Kozuch PL, Velayos FS, Baidoo L, Sparrow MP, Siegel CA. The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit all. *Clin Gastroenterol Hepatol*. 2010;8:655-9.
68. **Spiegel BM**, Bolus R, Harris L, Lucak S, Mayer E, Naliboff B, Esrailian E, Chey WD, Lembo A, Karsan H, Tillisch K, Dulai G, Talley J, Chang L. Characterizing abdominal pain attributes in IBS: guidance for study inclusion and outcome assessment. *Aliment Pharmacol Ther* 2010 Nov;32(9):1192-202 [Spiegel=Corresponding Author]
69. **Spiegel BM**, Bolus R, Agarwal N, Harris L, Lucak S, Sayuk G, Esrailian E, Chey WD, Lembo A, Karsan H, Tillisch K, Dulai G, Talley J, Chang L. Measuring symptoms in irritable bowel syndrome: development of a framework for clinical trials. *Aliment Pharmacol Ther* Nov;32(10):1275-91. [Spiegel=Corresponding Author]
70. Kaneshiro M, Ho A, Chan M, Cohen H, **Spiegel BM**. Colonoscopy yields fewer polyps as the day progresses despite using social influence theory to reverse the trend. *Gastrointest Endosc* 2010;72:1233-40. [Spiegel=Corresponding Author]
71. **Spiegel BMR**, Talley J, Shekelle P, Bolus R, Kurzbard N, Chan M, Ho A, Kaneshiro M, Cordasco K, Cohen H. Development and validation of a novel patient educational booklet to enhance colonoscopy preparation. *Am J Gastroenterol*. 2011 May;106(5):875-83
72. Au K, Singh MK, Bodulkam V, Bae S, Maranian P, Ogawa R, **Spiegel B**, McMahon M, Hahn B, Khanna D. Atherosclerosis in systemic sclerosis: a systematic review and meta-analysis. *Arthritis Rheum*. 2011 Jul;63(7):2078-90.
73. Solomon M, Bonafede M, Pan K, Wilson K, Beam C, Chakravarti P, **Spiegel B**. *Dig Dis Sci* 2011 Jun 30 [Epub ahead of print]

## RESEARCH PAPERS – PEER REVIEWED (IN PRESS)

1. None at this time.

## RESEARCH PAPERS – PEER REVIEWED (SUBMITTED)

2. vanOijen M; Laheij RJF; Targownik LE; Jansen JBM; Jansen JBM, Verheugt FWA, **Spiegel BMR**. Balancing Cardiovascular and GI Outcomes with Antiplatelet Therapy: A Cost-Effectiveness Analysis of Competing Strategies. Manuscript in secondary revision.
3. **Spiegel BMR**, Jacobson J, Esrailian E, Solomon M. Could Natural Orifice Transluminal Endoscopic Surgery (NOTES) Ever be Cost Effective vs. Laparoscopy (LAP)? A Hypothesis Generating Decision Analysis. Manuscript in primary submission.

## BOOKS

Spiegel B. Acing the GI Board Exam: The Ultimate Crunch-Time Resource. 2009 SLACK Inc. (currently in second printing)

Spiegel B and Karsan H. Acing the GI Board Exam: Hepatology. 2011 SLACK Inc.

Spiegel B and Karsan H. Acing the GI Board Exam: IBD Review. 2012 SLACK Inc (in preparation)

## BOOK CHAPTERS

1. Ferri FF Ed. PDxMD Gastroenterology [Book]. Philadelphia, Elsevier Sciences, 2003. **Contributor:**
  - Chapter 7: “Diverticular disease”
  - Chapter 13: “Irritable bowel syndrome”
  - Chapter 16: “Pancreatitis”
  - Chapter 17: “Peptic ulcer”
  - Chapter 19: “Proctitis”
2. **Spiegel BMR**, Dulai GS. Peptic ulcer disease and stress-related mucosal disease (chapter 80), In: Hospital Medicine; 2d ed. [Book]. Wachter B, Goldman L, Hollander H, eds. Lippincott, Williams & Wilkins, 2005
3. **Spiegel BMR**, Singh I. Gastrointestinal motility problems in the critical care setting. In: Intensive Care Medicine; 6<sup>th</sup> ed. [Book]. Irwin, Rippe, etd. Lippincott Williams & Wilkins, 2006

## LETTERS

1. **Spiegel B**. Meperidine or morphine in acute pancreatitis? [Letter]. *American Family Physician* 2001;64:219
2. **Spiegel BMR**, Gralnek IM. Potential bias in favor of coxibs [Letter Reply]. *Annals of Internal Medicine* 2004;140:761-2
3. **Spiegel BMR**, Targownik L, Dulai GS, Karsan HA, Gralnek IM. Endoscopic screening for esophageal varices in cirrhosis and the cost of variceal hemorrhage [Letter Reply]. *Hepatology* 2004
4. **Spiegel BMR**, Kanwal F. Premature to eliminate lamivudine in the treatment of hepatitis B [Letter Reply]. *Annals of Internal Medicine* 2005
5. Slavenburg S, Van Oijen MG, **Spiegel BM**. Comparison of health-related quality of life between populations. *Liver Int*. 2008;28:285-6.

## REVIEWS

1. **Spiegel BMR**, Gralnek IM. Evidence-based Gastroenterology [Book review]. *Gastroenterology* 2003;124:1996-19971.
2. **Spiegel BMR**. Negotiating the therapeutic staircase in inflammatory bowel disease. *The Gastroenterology Fellow* 2004;2:12-18
3. **Spiegel BMR**. Diagnosis and Management of Superior Mesenteric Artery Embolism. *The Gastroenterology Fellow* 2004;2:19-22
4. **Spiegel BMR**. The importance of the physician-patient relationship in functional gastrointestinal disorders. *International Foundation for Functional Gastrointestinal Disorders (IFFGD) Patient Review Material*, 2006
5. **Spiegel, BMR**; Horn JR; Mathis AS. Chronically questioned about chronic constipation? Postgraduate Institute of Medicine Special Report; May 2007
6. Ho, W; **Spiegel, BMR**. Obesity and Functional GI Disorders: Causation, Association or Neither? *Gastroenterology & Hepatology* 2008;4:527

7. Chey WD, Spiegel B Proton pump inhibitors, irritable bowel syndrome, and small intestinal bacterial overgrowth: coincidence or Newton's third law revisited? *Clin Gastroenterol Hepatol*. 2010 Jun;8(6):480-2. Epub 2010 Mar 19.
8. Laine L, **Spiegel B**, Rostom A, Moayyedi P, Kuipers EJ, Bardou M, Sung J, Barkun AN. Methodology for randomized trials of patients with nonvariceal upper gastrointestinal bleeding: recommendations from an international consensus conference. *Am J Gastroenterol*. 2010 Mar;105(3):540-50. Epub 2009 Dec 22. Review.
9. Agarwal N, **Spiegel BM**. The effect of irritable bowel syndrome on health-related quality of life and health care expenditures. *Gastroenterol Clin North Am*. 2011;40:11-9
10. **Spiegel BM**. How and when to prepare for the GI board examination. *Gastrointest Endosc* 2010;72:1250-2
11. **Spiegel BM**. Questioning the bacterial hypothesis of IBS: an epidemiological and evolutionary perspective. *Clinical Gastroenterology and Hepatology*. Jun;9(6):461-469.
12. **Spiegel B**. Two weeks of rifaximin relieves global symptoms and bloating in people with IBS without constipation. *Evid Based Med*. 2011 Apr 24 [Epub ahead of print].
13. **Spiegel BM**, Khanna D, Bolus R, Agarwal N, Khanna P, Chang L. Understanding gastrointestinal distress: a framework for clinical practice. *Am J Gastroenterol*. 2011 Mar;106(3):380-5.
14. **Spiegel BM**. Does time of day affect polyp detection rates from colonoscopy? *Gastrointest Endosc*. 2011 Mar;73(3):476-9.

## INVITED EDITORIALS

1. **Spiegel BM**. The impact of negative diagnostic tests in the management of non-ulcer dyspepsia: is no news good news? *Evidence-Based Gastroenterology* 2002;3:47-48
2. **Spiegel BM**, Gralnek IM. Early medical therapy reduces intra-gastric blood in upper gastrointestinal tract hemorrhage: a difference that makes a difference? *Evidence-Based Gastroenterology* 2002;3:40-41
3. **Spiegel BM**, Gralnek IM. Carvedilol or propranolol for variceal prophylaxis: Unconfidence intervals confound the choice. *Evidence-Based Gastroenterology* 2003;4:107-109
4. **Spiegel BM**. How much do coxibs cost? *Evidence-Based Gastroenterology* 2004;5:10-11
5. **Spiegel BM**, Dulai, GS. Rethinking the safety of clopidogrel: lessons learned from ulcers in Asia. *Evidence-Based Gastroenterology* 2005
6. **Spiegel BM**, Dulai GS. PPI therapy in nonulcer dyspepsia: still working after all these years. *Evidence-Based Gastroenterology* 2005
7. **Spiegel BM**. Barrett's esophagus and cancer: overview / overdone? *Audio-Digest Gastroenterology* 2006(Sept);20:9
8. **Spiegel BM**. Do physicians follow evidence-based guidelines in the diagnostic work-up of IBS? In Press at *Nature Clinical Practice Gastroenterology and Hepatology*.
9. **Spiegel, BM**. A letter a day keep the cancer away: improving colon cancer screening adherence with a mailed brochure. *Evidence-Based Gastroenterology* 2007.
10. **Spiegel BM**, Chey WD, Chang L. Bacterial overgrowth and irritable bowel syndrome: unifying hypothesis, or a spurious consequence of proton pump inhibitors? In press at *American Journal of Gastroenterology*.
11. **Spiegel BM**. Endoscopy for acute upper gastrointestinal tract hemorrhage: sooner is better. *Gastrointest Endosc*. 2009 Aug;70(2):236-9.

12. Chey WD, **Spiegel BM**. Proton pump inhibitor, irritable bowel syndrome, and small intestinal bacterial overgrowth: coincidence or Newton's third law revisited? *Clin Gastroenterol Hepatol*. 2010;8:480-2. 2
15. **Spiegel BM**. Treatment strategies for acid reflux: EncomPASSing practical solutions for primary care. *Am J Gastroenterol*. 2010;105:2347-9

**PUBLISHED ABSTRACTS**

1. **Spiegel BMR**, Ofman J. The effectiveness of early endoscopy for low-risk patients with non-variceal upper gastrointestinal hemorrhage: a systematic review. *Gastroenterology* 2000 118:A1324
2. **Spiegel BMR**, Vakil NB, Ofman JJ. Dyspepsia management in primary care: a reappraisal of competing strategies. *Gastroenterology* 2001;120:A261 [**oral presentation**]
3. **Spiegel BMR**, Targownik L, Karsan HA, Gralnek IM. Is universal screening endoscopy cost-effective in cirrhosis? *Gastrointestinal Endoscopy* 2002;55:A329 [**oral presentation**]
4. **Spiegel BMR**, Targownik L, Gralnek IM. The cost-effectiveness of COX-2 inhibitors in the management of chronic arthritis. *Gastroenterology* 2002;122:A443 [**oral presentation**]
5. **Spiegel BMR**, Ofman JJ, Vakil NB. Minimizing recurrent hemorrhage after hemostasis: the cost-effectiveness of competing strategies. *Gastroenterology* 2002;122:A329
6. Targownik L, **Spiegel BMR**, Karsan HA, Gralnek IM. The cost-effectiveness of hepatic venous pressure gradient (HVPG) monitoring in prevention of recurrent variceal bleeding (RVB). *Gastroenterology* 2002;122:A661
7. **Spiegel BMR**, Gralnek IM, Bolus R, Mayer E, Chang L, Dulai GS, Naliboff B. Is a negative colonoscopy associated with improved health-related quality of life or reassurance in irritable bowel syndrome? *Gastroenterology* 2003;124:A S1507
8. **Spiegel BMR**, Gralnek IM, Bolus R, Mayer E, Chang L, Naliboff B. Clinical determinants of health-related quality of life in irritable bowel syndrome. *Gastroenterology* 2003;124:A M1687
9. **Spiegel BMR**, Chiou CF, Ofman JJ. Minimizing complications from nonsteroidal anti-inflammatory drugs: the cost-effectiveness of competing strategies in varying risk groups. *American Journal of Gastroenterology* 2003;A277
10. Targownik L, **Spiegel BMR**, Dulai GS, Gralnek IM, Farrell J. The cost-effectiveness of endoscopic colonic stents in the management of acute malignant large bowel obstruction. *American Journal of Gastroenterology* 2003;A41
11. **Spiegel BMR**, Targownik LE, DeRosa V, Dulai GS, Gralnek IM, Chiou CF. The quality of published health economic analyses in digestive diseases: a systematic review and quantitative appraisal. Digestive Disease Week 2004.
12. **Spiegel BMR**, DeRose VP, Gralnek IM, Wang V, Dulai GS. Is it worth screening for celiac sprue in irritable bowel syndrome? A cost-effectiveness analysis. Digestive Disease Week 2004. [**oral presentation – Distinguished Abstract Plenary Session**]
13. Kanwal F, **Spiegel BMR**, Gralnek IM, Dulai GS, Martin P. Adefovir salvage therapy is cost-effective in chronic hepatitis B. Digestive Disease Week 2004. [**oral presentation**]
14. Lewis B, Legnani P, Gralnek IM, **Spiegel BMR**. Crohn's disease capsule scoring index: a new disease activity scale. Digestive Disease Week 2004.
15. **Spiegel BMR**, Farid M, Dulai GS, Gralnek IM, Kanwal F. Comparing rates of dyspepsia with coxibs versus NSAID+PPI: A Systematic Review and Meta-Analysis of Clinical Trial Data. Digestive Disease Week 2005. [**oral presentation**]
16. **Spiegel BMR**, Lim B, Dulai GS, Mann N, Kanwal F, Gralnek IM. The cost-effectiveness of IV versus PO proton pump inhibitor therapy in the management of high risk ulcer hemorrhage. Digestive Disease Week 2005.
17. **Spiegel BMR**, Kanwal F, Naliboff B, Mayer E. The impact of somatization on the use of gastrointestinal healthcare resources in irritable bowel syndrome. Digestive Disease Week 2005. [**oral presentation**]

18. **Spiegel BMR**, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. The impact of hepatitis C on health related quality of life: a systematic review of the literature. *Digestive Disease Week* 2005.
19. Kanwal F, Gralnek IM, Dulai GS, Han S, **Spiegel BMR**. The impact of gender on access to liver transplantation in the MELD era. *Digestive Disease Week* 2005.
20. Esrailian E, Targownik LE, **Spiegel BMR**, Glassman P, Dubinsky MC, Targan SR, Gralnek IM. Significant variation exists in the process of care in Crohn's Disease (CD) among North American experts in Inflammatory Bowel Disease (IBD): a clinical vignette study. *Digestive Disease Week* 2005.
21. Esrailian E, Targownik LE, **Spiegel BMR**, Glassman P, Dubinsky MC, Targan SR, Gralnek IM. Is endoscopic ultrasound (EUS) appropriate for the diagnosis of perianal fistulas in Crohn's Disease (CD)? A survey of North American Inflammatory Bowel Disease (IBD) experts. *Digestive Disease Week* 2005.
22. Esrailian E, Targownik LE, **Spiegel BMR**, Glassman P, Dubinsky MC, Targan SR, Gralnek IM. Is Wireless Capsule Endoscopy (WCE) Appropriate for the Diagnosis and Management of Crohn's Disease (CD)? A Survey of North American Inflammatory Bowel Disease (IBD) Experts. *Digestive Disease Week* 2005. [oral presentation]
23. Gralnek IM, Dulai GS, Fennerty B, **Spiegel BMR**. Esomeprazole *versus* Alternative Proton Pump Inhibitors (PPI) in Erosive Esophagitis (EE): A Meta-Analysis of Trials Reporting Healing Rates and Symptom Relief. Abstract accepted to American College of Gastroenterology meeting, 2005 [Presidential Abstract]
24. **Spiegel BMR**, Bolus R, Han S, Kanwal F. Initial content validation of a disease-targeted health-related quality of life (HRQOL) instrument in chronic hepatitis B virus (HBV) infection. Abstract accepted to Asia-Pacific ISPOR Conference, 2006.
25. **Spiegel BMR**, Naliboff B, Mayer E, Bolus R, Gralnek I, Shekelle P. The effectiveness of a model physician-patient relationship in veterans with irritable bowel syndrome. VA Health Services Research and Development (HSR&D) Annual National Meeting, 2006 [oral presentation]
26. **Spiegel BMR**, Naliboff B, Mayer E, Bolus R, Gralnek I, Shekelle P. The effectiveness of a model physician-patient relationship versus usual care in irritable bowel syndrome: a randomized controlled trial. *Gastroenterology* 2006;130:A773 [oral presentation]
27. **Spiegel BMR**, Naliboff, Mayer E, Bolus R, Chang L. Development and initial validation of a concise point-of-care IBS severity index: the 4-item "BEST" questionnaire. *Gastroenterology* 2006;130:S1040
28. **Spiegel BMR**, Huang E, Esrailian E. The cost-effectiveness of competing therapies for hepatic encephalopathy: a decision analysis. *Gastroenterology* 2006;130:M1031
29. **Spiegel BMR**, Esrailian. The budget impact of screening for esophageal varices with capsule endoscopy. *Gastroenterology* 2006;130:A263 [oral presentation]
30. **Spiegel BMR**, Farid M, Esrailian E, Talley J, Chang L. Is irritable bowel syndrome a diagnosis of exclusion? A vignette-based survey of IBS experts *versus* non-experts. *Gastroenterology* 2006;130:A770 [oral presentation]
31. **Spiegel BMR**, Farid M, Esrailian E, Talley J, Chang L. Appropriateness of diagnostic testing in IBS: provider beliefs do not match published guidelines. *Gastroenterology* 2006;130:S1134
32. Esrailian E, **Spiegel BMR**, Targownik LE, P, Dubinsky MC, Targan SR, Gralnek IM. North American Inflammatory Bowel Disease (IBD) Experts and Community Providers Are Consistent in their Use of Diagnostic Tests in Crohn's Disease (CD). *Gastroenterology* 2006;130:S1361
33. Esrailian E, **Spiegel BMR**, Targownik LE, P, Dubinsky MC, Targan SR, Gralnek IM. North American Inflammatory Bowel Disease (IBD) Experts and Community GI Providers Differ Significantly in Prescribing 5-ASA Products in Crohn's Disease (CD). *Gastroenterology* 2006;130:W1051

34. **Spiegel BMR**, Bolus R, Han S, Kanwal F. Initial content validation of a disease-targeted health-related quality of life (HRQOL) instrument in chronic hepatitis B virus (HBV) infection. Abstract accepted to Digestive Disease Week, 2006. *Gastroenterology* 2006;130:S1040
35. Singh H, Targownik LE, Latosinsky S, **Spiegel BM**. The cost-effectiveness of colonic stenting as a bridge to curative surgery in patients with acute left-sided malignant colonic obstruction: a Canadian perspective. *Gastroenterology* 2006;130:A715 [[oral presentation](#)]
36. Chang L, Alvarado C, Mayer EA, van Oijen MG, Liu C, **Spiegel B**. Women with irritable bowel syndrome (IBS) in pre- and post-menopausal age groups report similar gastrointestinal (GI) symptoms. *Gastroenterology* 2006;130:T1282
37. **Spiegel BM**, Tan J, Lim B, Farid M, Singh I, van Oijen MG. Incident Dyspepsia in the Treatment of Peptic Ulcer Disease: A Meta-Analysis Comparing H. Pylori (HP) Eradication *versus* Proton Pump Inhibitor (PPI) Therapy. *Gastroenterology* 2006;130:W1072
38. **Spiegel BM**, Gralnek IM, Laine L, Jensen D, Dulai GS, Eisen G, Esrailian E. Practice patterns of antisecretory use in high-risk nonvariceal upper GI hemorrhage (NVUGIH): results of a national vignette survey. DDW 2007.
39. **Spiegel BM**, Strickland A, Chang L. Predictors of Patient-Assessed Illness Severity in Irritable Bowel Syndrome (IBS). DDW 2007.
40. **Spiegel BM**, Gralnek IM, Laine L, Jensen D, Dulai GS, Eisen G, Esrailian E. Adherence to “best practices” in nonvariceal upper GI hemorrhage (NVUGIH): a national vignette survey of experts versus community providers. DDW 2007. [[oral presentation](#)]
41. **Spiegel BM**, Gralnek IM, Laine L, Jensen D, Dulai GS, Eisen G, Esrailian E. Endoscopic hemostasis practices in nonvariceal upper GI hemorrhage (NVUGIH): results of a national vignette survey. DDW 2007.
42. **Spiegel BM**, Gralnek IM, Laine L, Jensen D, Dulai GS, Eisen G, Esrailian E. Extreme variations in pre-endoscopic care of high-risk nonvariceal upper GI hemorrhage (NVUGIH): results of a national vignette survey of experts versus community providers. DDW 2007.
43. **Spiegel BM**, Chang L, Kanwal F. Is Asking “*How are you doing*” enough to capture health related quality of life (HRQOL) and overall severity in irritable bowel syndrome (IBS)? DDW 2007. [[oral presentation](#)]
44. **Spiegel BM**, Glassman P, Dulai G, Shekelle P, Ochotorena L, Talley J, Goldzweig C. Improving adherence with PPI prescribing guidelines in high-risk NSAID Users: a controlled “before and after” study of an electronic medical reminder. DDW 2007. [[oral presentation](#)]
45. **Spiegel BM**, Strickland A, Chang L. Predictors of patient-assessed symptom severity in irritable bowel syndrome. DDW 2007.
46. Kanwal F, Hoang T, **Spiegel BM**, Eisen S, Gifford A, Asch S. Predictors of treatment among patients with chronic hepatitis C virus infection. DDW 2007.
47. vanOijen M, Laheij RJF; Targownik LE; Jansen JBM; Jansen JBM, Verheugt FWA, **Spiegel BMR**. Balancing Cardiovascular and GI Outcomes with Antiplatelet Therapy: A Cost-Effectiveness Analysis of Competing Strategies. DDW 2007. [[oral presentation – Distinguished Abstract Plenary Session](#)]
48. Desai A, Bolus R, Nissenson A, Bolus S, Solomon M, Khawar O, Talley J, **Spiegel B**. Do dialysis facilities cherry pick their patients to improve outcomes? Results of a national provider survey. Accepted to American Society of Nephrology (ASN) meeting 2007. [[oral presentation](#)]
49. Desai A, Bolus R, Nissenson A, Bolus S, Solomon M, Khawar O, Talley J, **Spiegel B**. Variation in perceived importance of clinical performance measures in dialysis: results of a national provider survey. Accepted to American Society of Nephrology (ASN) meeting 2007.

50. Desai A, Bolus R, Nissenson A, Bolus S, Solomon M, Khawar O, Talley J, **Spiegel B**. Perceptions regarding optimal frequency of hematocrit (HCT) testing in dialysis: results of a national provider survey. Accepted to American Society of Nephrology (ASN) meeting 2007.
51. Desai A, Bolus R, Nissenson A, Bolus S, Solomon M, Khawar O, Talley J, **Spiegel B**. Is the dialysis facility an appropriate setting to administer routine health maintenance services? Perceptions from a national provider survey. Accepted to American Society of Nephrology (ASN) meeting 2007.
52. **Spiegel BMR**, Patel Vaishali, Chiou Chiun-Fang, Esrailian E. Using Cost-Utility Analysis to Assess the Budget Impact of Biologics for the Treatment of Psoriasis (PSO). Abstracted submitted to ISPOR 2007.
53. **Spiegel BMR**, Chan M, Shekelle P, Aberbrook M, Cohen H. Adherence to colonoscopy quality indicators in a large regional VA healthcare system. VA HSR&D National Meeting, 2008. [**oral presentation**]
54. Ford A, Talley NJ, **Spiegel BMR**, Foxx-Orenstein A, Schiller L, Quigley EMM, Moayed P. Efficacy of fiber in irritable bowel syndrome: systematic review and meta-analysis. Abstracted submitted to ACG 2008.
55. Ford A, Talley NJ, **Spiegel BMR**, Foxx-Orenstein A, Schiller L, Quigley EMM, Moayed P. Efficacy of antispasmodics and peppermint oil in irritable bowel syndrome: systematic review and meta-analysis. Abstracted submitted to ACG 2008.
56. Ford A, Chey W, Talley NJ, Malhotra A, **Spiegel BMR**, Moayed P. Utility of diagnostic tests for celiac disease in irritable bowel syndrome: systematic review and meta-analysis. Abstracted submitted to ACG 2008.
57. **Spiegel BMR**, Bolus R, Desai A, Zagar P, Parker T, Moran J, Solomon M, Khawar O, Gitlin M, Nissenson A. Dialysis practices that distinguish top vs. Bottom performing facilities by Kt/V. Abstracted submitted to American Society of Nephrology meeting 2008.
58. **Spiegel BMR**, Bolus R, Desai A, Zagar P, Parker T, Moran J, Solomon M, Khawar O, Gitlin M, Nissenson A. Dialysis practices that distinguish top vs. Bottom performing facilities by Hgb. Abstracted submitted to American Society of Nephrology meeting 2008.
59. Karsan S, Huang E, Singh I, Ho W, Makhani M, **Spiegel BMR**. Do Frequent Hemoglobin (Hgb) Checks Improve Outcomes in GI Hemorrhage? *Gastroenterology* 2008;134:AB185 [**oral presentation**]
60. Chan MY, Cohen H, **Spiegel, BMR**. Does the First Colonoscopy of the Day Yield More Polyps than Cases Performed Later? *Gastroenterology* 2008;134:AB211 [**oral presentation – AGA Clinical Plenary**]
61. **Spiegel BMR**, Harris L, Lucak S, Mayer E, Naliboff B, Bolus R, Esrailian E, Chey WD, Lembo A, Karsan H, Tillisch K, Derezin M, Dulai G, Strickland A, Talley J, Chang L. EuroQOL Utilities Demonstrate Excellent Validity and Responsiveness in IBS: Results from the PROOF Cohort. *Gastroenterology* 2008;134:AB156 [**oral presentation**]
62. **Spiegel BMR**, Harris L, Lucak S, Mayer E, Naliboff B, Bolus R, Esrailian E, Chey WD, Lembo A, Karsan H, Tillisch K, Derezin M, Dulai G, Strickland A, Talley J, Chang L. Predictors of Work Productivity in Irritable Bowel Syndrome (IBS): Results from the PROOF Cohort. *Gastroenterology* 2008;134:AB157 [**oral presentation**]
63. **Spiegel BMR**, Harris L, Lucak S, Mayer E, Naliboff B, Bolus R, Esrailian E, Chey WD, Lembo A, Karsan H, Tillisch K, Derezin M, Dulai G, Strickland A, Talley J, Chang L. Measuring IBS Patient Reported Outcomes with a Single Item Numeric Rating Scale: Results from the PROOF Cohort. *Gastroenterology* 2008;134:AB1026 [**poster of distinction**]
64. **Spiegel BMR**, Farid M, van Oijen MGH, Laine L, Howden CW, Esrailian E. Adherence to “Best Practices” in Dyspepsia Management: A National Vignette Survey of Internists, Nurse Practitioners, Community Gastroenterologists and Experts. *Gastroenterology* 2008;134:AB1040 [**poster of distinction**]

65. **Spiegel BMR**, Farid M, van Oijen MGH, Laine L, Howden CW, Esrailian E. Providers Disagree about Risk of Adverse Events with PPIs, and Beliefs Predict Adherence vs. Non-Adherence with “Best Practices” in Dyspepsia Management. *Gastroenterology* 2008;134:AB1086
66. **Spiegel BMR**, Ho W, Esrailian E, Melmed G, Higgins P, Siegel C, Dubinsky M, Targan S. Practice Patterns of 5-ASA Use in Ulcerative Colitis (UC): Results of a National Vignette Survey Comparing Experts vs. Community Providers. *Gastroenterology* 2008;134:AB1243
67. **Spiegel BMR**, Ho W, Esrailian E, Melmed G, Higgins P, Siegel C, Dubinsky M, Targan S. Experts and Community Providers Have Varying Beliefs about the Appropriateness of Colectomy for Flat Low Grade Dysplasia in Ulcerative Colitis (UC). *Gastroenterology* 2008;134:AB1133
68. Weinberg BM, Farrell J, Tang R, Dawson D, Reber H, Hines J, **Spiegel BMR**. Are We Performing Fewer Unnecessary Operations for Pancreatic Cysts? Time Trends and Analysis from a Large Cohort. *Gastroenterology* 2008;134:AB1418
69. Solomon M, Jacobson JO, Esrailian E, **Spiegel BMR**. Projected Impact of NOTES on Patient Throughput, Resource Utilization, and Physician Reimbursement: Results of a Hypothesis-Generating Discrete-Event Queuing Model. *Gastroenterology* 2008;134:AB1117
70. **Spiegel BMR**, Jacobson J, Esrailian E, Solomon M. Could Natural Orifice Transluminal Endoscopic Surgery (NOTES) Ever be Cost Effective vs. Laparoscopy (LAP)? A Hypothesis Generating Decision Analysis. *Gastroenterology* 2008;134:AB736 [**oral presentation**]
71. **Spiegel, BMR**, Shekelle P, Talley J, Chan M, Cohen H. Impact of a Novel Patient Educational Booklet on Colonoscopy Preparation in Veterans. VA HSR&D National Meeting 2009. [**oral presentation –Plenary Abstract Session**]
72. **Spiegel, BMR**, Shekelle P, Talley J, Chan M, Cohen H. Impact of a Novel Patient Educational Booklet on Colonoscopy Preparation in Veterans. Digestive Disease Week 2009, Chicago IL. [**oral presentation**]
73. **Spiegel, BMR**, Shekelle P, Talley J, Chan M, Cohen H. Impact of a Novel Patient Educational Booklet on Colonoscopy Preparation in Veterans. VA HSR&D National Meeting 2009. [**oral presentation –Plenary Abstract Session**]
74. **Spiegel, BMR**, Shekelle P, Talley J, Chan M, Cohen H. Impact of a Novel Patient Educational Booklet on Colonoscopy Preparation in Veterans. Digestive Disease Week 2009 [in press at *Gastroenterology*]. [**oral presentation**]
75. **Spiegel BMR**, Bolus R, Camilleri M, on behalf of the Rome Foundation Outcomes and Endpoints Working Group Results of the Rome Endpoints Working Group. Impact of Baseline Severity on the Performance of IBS Clinical Trial Endpoints: Results of the Rome Endpoints Working Group Meta-Analysis. Digestive Disease Week 2009. [**oral presentation**]
76. **Spiegel BMR**, Bolus R, Camilleri M, on behalf of the Rome Foundation Outcomes and Endpoints Working Group Results of the Rome Endpoints Working Group. Performance of Competing IBS Trial Endpoints Depends on IBS Sub-Type: Results of the Rome Foundation Endpoints Working Group Meta-Analysis. Digestive Disease Week 2009. [**oral presentation**]
77. Karsan S, Kanwal F, Huang E, Skingh I, Ho W, Makhani M, Strickland A, **Spiegel BMR**. Early Endoscopy Predicts Lower Mortality in Acute Gastrointestinal Hemorrhage. Digestive Disease Week 2009.
78. Karsan S, Kanwal F, Huang E, Skingh I, Ho W, Makhani M, Strickland A, **Spiegel BMR**. Does the Completion of Nasogastric Lavage (NGL) Improve Outcomes in GI Hemorrhage? Digestive Disease Week 2009.
79. Adeyemo L, **Spiegel BMR**, Chang L. Do IBS Symptoms Vary Between Men and Women? A Meta-Analysis. Digestive Disease Week 2009.

80. Foster T, Kanwal F, Han S, **Spiegel BMR**. Are High Risk Individuals Appropriately Screened for Hepatitis B Virus (HBV) Infection? A Survey of Physician Knowledge, Attitudes and Beliefs about CDC Guidelines. Digestive Disease Week 2009.
81. Chan MY, Cohen H, **Spiegel BMR**. Colonoscopy Yields Fewer Polyps as the Day Progresses Despite Use of Social Influence to Reverse the Trend. Digestive Disease Week 2009.
82. Kanwal F, Gralnek I, Asch S, Barkun A, Kuipers E, Bardou M, Sung J, **Spiegel BMR**. Measuring Quality of Care in Patients with Nonvariceal Upper GI Hemorrhage (NVUGIH): Development of an Explicit Quality Indicator Set. Digestive Disease Week 2009.
83. Melmed G, Ippoliti A, Vasiliauskas EA, McGovern DP, Dubinsky M, Simpson P, Targan S, **Spiegel BMR**. A Single-Item 10-point Numeric Rating Scale Shows Excellent Correlation with Measures of Crohn's Disease Activity and Health-Related Quality of Life. Digestive Disease Week 2009.
84. Ford AC, Talley NJ, **Spiegel BMR**, Moayyedi P. Prevalence of Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: Systematic Review and Meta-Analysis. Digestive Disease Week 2009. **[oral presentation]**
85. Hong S, Mann N, Chey WD, Chang L, **Spiegel B**. Do proton pump inhibitors (PPIs) predispose to the development of SIBO in IBS versus non-IBS patients? Am J Gastroenterol 2009;104:S103 (Ab#269).
86. Hong S, Mann N, Chey WD, Chang L, **Spiegel B**. Is IBS a predictor of SIBO as identified by hydrogen/methane breath testing? Am J Gastroenterol 2009;104:S110 (Ab#289).
87. **Spiegel BMR**, Harris L, Lucak S, Mayer E, Naliboff B, Bolus R, Esrailian E, Chey WD, Lembo A, Karsan H, Tillisch K, Derezin M, Dulai G, Strickland A, Talley J, Chang L. Characterizing Abdominal Pain Attributes in IBS: Guidance for Study Inclusion Criteria and Outcome Measurement. Digestive Disease Week 2010. **[oral presentation]**
88. **Spiegel BMR**, Harris L, Lucak S, Mayer E, Naliboff B, Bolus R, Esrailian E, Chey WD, Lembo A, Karsan H, Tillisch K, Derezin M, Dulai G, Strickland A, Talley J, Chang L. Pain vs. Discomfort in IBS: Do Patients Understand the Difference? Digestive Disease Week 2010.
89. **Spiegel BMR**, Harris L, Lucak S, Mayer E, Naliboff B, Bolus R, Esrailian E, Chey WD, Lembo A, Karsan H, Tillisch K, Derezin M, Dulai G, Strickland A, Talley J, Chang L. Patient Willingness to Use ROSE-010: A Subcutaneous (SC) GLP-1 Analogue for IBS Pain Episodes. Digestive Disease Week 2010.
90. **Spiegel BMR**, Harris L, Lucak S, Mayer E, Naliboff B, Bolus R, Esrailian E, Chey WD, Lembo A, Karsan H, Tillisch K, Derezin M, Dulai G, Strickland A, Talley J, Chang L. Patient-Reported Symptom Relief from Current Therapy is a Robust Marker of Illness Severity in IBS. Digestive Disease Week 2010. **[oral presentation]**
91. **Spiegel BMR**, Harris L, Lucak S, Mayer E, Naliboff B, Bolus R, Esrailian E, Chey WD, Lembo A, Karsan H, Tillisch K, Derezin M, Dulai G, Strickland A, Talley J, Chang L. Characterizing "Bowel Urgency:" Guidance for Outcome Assessment in D-IBS. Digestive Disease Week 2010.
92. Gupta G, Bolus R, Talley J, Jedel S, Alvarez E, Snyder B, **Spiegel BM**. Is there an Association between Post-Traumatic Stress Disorder or Depression and Inflammatory Bowel Disease among U.S. Veterans? Digestive Disease Week 2010.
93. Karsan S, Kanwal F, Nordstrom C, Nguyen D, Huang E, Singh I, Ho W, Makhani M, Strickland A, **Spiegel B**. The Impact of Elevated INR on Outcomes in GI Hemorrhage. Digestive Disease Week 2010. **[oral presentation]**